# Author Manuscript

Crit Rev Biochem Mol Biol. Author manuscript; available in PMC 2017 September 05.

Published in final edited form as:

Crit Rev Biochem Mol Biol. 2016; 51(6): 413–439. doi:10.1080/10409238.2016.1204980.

# Connexins and their channels in inflammation

Joost Willebrords<sup>#1</sup>, Sara Crespo Yanguas<sup>#1</sup>, Michaël Maes<sup>1</sup>, Elke Decrock<sup>2</sup>, Nan Wang<sup>2</sup>, Luc Leybaert<sup>2</sup>, Brenda R. Kwak<sup>3</sup>, Colin R. Green<sup>4</sup>, Bruno Cogliati<sup>5</sup>, and Mathieu Vinken<sup>1,\*</sup>

<sup>1</sup>Department of *In Vitro* Toxicology and Dermato-Cosmetology, Vrije Universiteit Brussel, Laarbeeklaan 103, 1090 Brussels, Belgium; Joost Willebrords: + Tel: 32 2 477 45 87, Michaël Maes: Tel: +32 2 477 45 87, Sara Crespo Yanguas: Tel: +32 2 477 45 87

<sup>2</sup>Department of Basic Medical Sciences, Physiology Group, Ghent University, De Pintelaan 185, 9000 Ghent, Belgium; Elke Decrock: Tel: +32 9 332 39 73, Nan Wang: Tel: +32 9 332 39 38, Luc Leybaert: Tel: +32 9 332 33 66

<sup>3</sup>Department of Pathology and Immunology and Division of Cardiology, University of Geneva, Rue Michel-Servet 1, CH-1211 Geneva, Switzerland; Brenda R. Kwak: Tel: +41 22 379 57 37

<sup>4</sup>Department of Ophthalmology and New Zealand National Eye Centre, University of Auckland, New Zealand; Colin R. Green: Tel: +64 9 923 61 35

<sup>5</sup>Department of Pathology, School of Veterinary Medicine and Animal Science, University of São Paulo, Av. Prof. Dr. Orlando Marques de Paiva 87, 05508-270 São Paulo, Brazil; Bruno Cogliati: Tel: +55 11 30 91 12 00

<sup>#</sup> These authors contributed equally to this work.

# Abstract

Inflammation may be caused by a variety of factors and is a hallmark of a plethora of acute and chronic diseases. The purpose of inflammation is to eliminate the initial cell injury trigger, to clear out dead cells from damaged tissue and to initiate tissue regeneration. Despite the wealth of knowledge regarding the involvement of cellular communication in inflammation, studies on the role of connexin-based channels in this process have only begun to emerge in the last few years. In this paper, a state-of-the-art overview of the effects of inflammation on connexin signaling is provided. *Vice versa*, the involvement of connexins and their channels in inflammation will be discussed by relying on studies that use a variety of experimental tools, such as genetically modified animals, small interfering RNA and connexin-based channel blockers. A better understanding of the importance of connexin signaling in inflammation may open up towards clinical perspectives.

### Keywords

Connexins; gap junctions; hemichannels; inflammation; cytokines

<sup>&</sup>lt;sup>\*</sup>Corresponding author: Mathieu Vinken: mathieu.vinken@vub.ac.be; Tel: +32 2 477 45 87. **Declaration of interest** 

The authors report no declarations of interest.

# 1 Introduction

In multicellular organisms, homeostasis is controlled by 3 communication mechanisms acting at the intracellular, extracellular and intercellular level. The latter is mainly mediated by gap junctions (GJs) (Su and Lau, 2014), which appear as plaques at the cell plasma membrane surface and are formed by the interaction of 2 hemichannels (HCs), one contributed by each of the adjacent cells (Vinken et al., 2006, Vinken et al., 2011). Each HC is composed of 6 connexins (Cxs), which are transmembrane (TM) proteins consisting of a cytoplasmic loop (CL), 2 extracellular loops (EL), a cytoplasmic C-terminal tail and a cytoplasmic N-terminal tail (Vinken et al., 2012, Maes et al., 2014). More than 20 different Cx species have been identified in human and they are all named after their predicted molecular weight, expressed in kilodaltons. GJs allow the intercellular transfer of small and hydrophilic molecules with a molecular weight below 1-1.5 kilodalton, such as adenosine triphosphate (ATP), inositol triphosphate and cyclic adenosine monophosphate, as well as ions. This flux is called gap junctional intercellular communication (GJIC) (Decrock et al., 2009, Chandrasekhar and Bera, 2012, Wang et al., 2013b). The latter can be regulated by different mechanisms including pH, transmembrane voltage and calcium concentration (Cottrell and Burt, 2005). Posttranslational modifications, such as S-nitrosylation, sumoylation and phosphorylation, also directly regulate gap junction opening (Johnstone et al., 2012). Upon degradation, gap junctional channels are internalized by one of the 2 opposing cells, resulting in the formation of an annular gap junction. These structures are further degraded by both lysosomes and proteasomes (Laird, 2005, Laird, 2006). When unopposed, HCs have the potential to form a transmembrane conduit between the cytosol of an individual cell and its extracellular environment, and to convey a number of critical molecules, including ATP, nicotinamide adenine dinucleotide, glutamate and prostaglandins (Figure 1) (Wang et al., 2013b). While GJs are usually open in physiological conditions, HCs are typically closed yet can be activated by a number of pathological triggers, such as increases membrane depolarization, increases in intracellular calcium (De Vuyst et al., 2006, Wang et al., 2013a) or decrease in extracellular calcium concentration (Srinivas et al., 2006), mechanical stimulation (Luckprom et al., 2011), changes in Cx phosphorylation status (Alstrom et al., 2015), oxidative stress (Riquelme and Jiang, 2013), ischemia/reperfusion insults (Wang et al., 2013c) and inflammatory conditions (Takeuchi and Suzumura, 2014, Calder et al., 2015). Cx proteins can also affect cellular functions independently of their channel-forming properties by altering the expression of homeostasis determinants or by direct interaction with cell growth and cell death regulators through binding of cytoplasmic proteins to the C-terminal tail (Vinken et al., 2012, De Bock et al., 2015).

Interesting experimental and therapeutic tools are the peptide inhibitors of connexin-based channels, especially those who mimic specific connexin sequences. In contrast to carbenoxolone, a typical inhibitor of GJs and connexin-based HC's, these mimetic peptides have better selectivity. Over the past ten years, several peptides have been demonstrated to block hemichannels, including Gap26, a peptide identical to a sequence on the first EL of Cx43 (Wang *et al.*, 2013a), Gap27, a peptide identical to a sequence on the second EL of Cx37 and Cx43 (De Bock *et al.*, 2011), Peptide5, a Cx43 HC-blocking mimetic peptide

(Danesh-Meyer *et al.*, 2012) and Gap19, a synthetic nonapeptide that mimics a sequence in the cytoplasmic loop area of Cx43 (Wang *et al.*, 2013a).

Inflammation is a first-line mechanism in the innate immune response in order to protect the organism against pathogens and deleterious effects of cell damage. This complex process encompasses a multistep reaction, involving recruitment of immune cells, vasodilatation, increased permeability and an extensive set of molecular mediators. Its goal is to eliminate the initial cause of cell injury, clear out necrotic cells damaged upon the insult and to initiate tissue repair (Toskala, 2014, Shalapour and Karin, 2015, Waisman et al., 2015). Both microbiologically-induced inflammation and sterile inflammation are characterized by the recruitment of neutrophils and macrophages as well as by the production of inflammatory cytokines and chemokines (Chen and Nuñez, 2010). In particular, Toll-like receptors are expressed on various immune cells, such as macrophages, dendritic cells, B-cells and neutrophils, and on non-immune cells in brain, heart, intestine, lung, liver and kidney (Kawai and Akira, 2007, Vaure and Liu, 2014). Toll-like receptors constitute a family of primary sensors that detect damage-associated molecular patterns (DAMPs) (Chen and Nuñez, 2010), released by damaged cells, or pathogen-associated molecular patterns (PAMPs), like peptidoglycan from most bacteria and lipopolysaccharide (LPS) from Gramnegative bacteria (Akira et al., 2006, Kawai and Akira, 2007, Lu et al., 2008). Toll-like receptor activation occurs through receptor dimerization, which requires cluster of differentiation 14 and myeloid differentiation factor 2. Subsequently, the transcription factor nuclear factor (NF) k-light-chain-enhancer of activated B cells kB, present in the cytosol under basal conditions, becomes activated and transported to the nucleus. At this location, NF-*k*B regulates the expression of cytokines, cyclo-oxygenase 2, growth factors and inhibitors of apoptosis and the expression of pro-interleukin (IL)-1 $\beta$ , which is then cleaved in the cytosol by caspase 1 to active IL-1 $\beta$  (Figure 2). Finally, the latter is released in the extracellular environment and can induce the production of an array of pro-inflammatory mediators, such as IL-6, tumor necrosis factor (TNF)-a and nitric oxide synthase (NOS), leading to NO formation (Lucas and Maes, 2013).

In the last decade, it has become clear that the inflammatory response relies, at least in part, on cellular communication mediated by Cx proteins and their channels (Tables 2 and 3) (Chanson *et al.*, 2005, Brisset *et al.*, 2009, Morel *et al.*, 2009, Scheckenbach *et al.*, 2011, Maes *et al.*, 2015b, Meens *et al.*, 2015). This paper will give an overview of these aspects in different organs.

### 2 Connexin signaling and inflammation

#### 2.1 Brain and spinal cord

**2.1.1 Effects of inflammation on connexins and their channels in the brain and spinal cord**—The brain is a highly differentiated, heterogeneous and complex organ that requires various control mechanisms, including cellular communication through Cx-based channels (Table 1) (Scheckenbach *et al.*, 2011). In the brain, Cx43 is most prominently produced by astrocytes, while microglial cells mainly harbor Cx32 and Cx26 (Giaume and Theis, 2010, Takeuchi and Suzumura, 2014). A number of other Cxs, including Cx26, Cx30, Cx40, Cx45 and Cx46, have been detected in astrocytes *in vitro* (Kunzelmann

*et al.*, 1997, Dermietzel *et al.*, 2000). Brain oligodendrocytes express Cx32, Cx47 and Cx29, whereas neurons produce Cx36 and Cx45 (Moore and O'Brien, 2015). The blood-brain barrier is a selective permeability barrier that separates circulating blood from the brain extracellular fluid. The blood-brain barrier is formed by endothelial cells and pericytes, which express Cx37, Cx40 and Cx43, as well as by astrocytes that express Cx43, Cx30 and Cx26 in decreasing order (Traub *et al.*, 1998, Nagasawa *et al.*, 2006, De Bock *et al.*, 2014). In the spinal cord, developing motor neurons show expression of Cx36, Cx37, Cx40, Cx43, and Cx45 mRNA (Tonkin *et al.*, 2014). Spinal astrocytes contain Cx30 and Cx43, and spinal oligodendrocytes stain positive for Cx29, Cx32 and Cx47.

Upon peripheral injury, pro-inflammatory cytokines are released into the blood circulation and attract leukocytes (Chanson et al., 2005). These cytokines make the blood-brain barrier more permeable, resulting in the invasion of blood cells into the central nervous system and hence the occurrence of neuro-inflammation (Takeuchi and Suzumura, 2014). In Rasmussen encephalitis, a rare condition characterized by sustained brain inflammation, epilepsy and progressive cognitive deterioration in children, expression of Cx32 in brain tissue is decreased, while Cx26 production remains unchanged. Interestingly, GJ coupling in cortical pyramidal neurons in brain tissue from Rasmussen encephalitis patients is enhanced (Cepeda et al., 2015). Demyelination, being the loss of myelin surrounding the nerves, is a hallmark of some neurodegenerative auto-immune diseases, including multiple sclerosis, encephalomyelitis and chronic inflammatory demyelinating polyneuropathy. As such, inflammation may drive demyelination associated with such diseases through overproduction of cytokines via upregulation of TNF-a (Ledeen and Chakraborty, 1998). In this regard, Cx32-based and Cx47-based GJ formation in oligodendrocytes is compromised within lesions in multiple sclerosis patients, while Cx30 and Cx43 levels are augmented as part of astrogliosis (Markoullis et al., 2012b, Lieury et al., 2014, Markoullis et al., 2014). Moreover, Cx32 production is downregulated along myelinated fibers, yet Cx47 shows enhanced expression mainly in oligodendrocyte precursor cells (Markoullis et al., 2012b). Similar changes in Cx expression patterns are observed in an experimental model of autoimmune encephalomyelitis in mouse (Markoullis et al., 2012a). LPS injection in rats shows that activation of apoptosis in oligodendrocytes is an early event in demyelination concomitant with loss of Cx43 in the corpus callosum (Zhang et al., 2013a). Astrocytes are of importance in initiating and regulating the release of pro-inflammatory cytokines, including IL-1ß and TNF-a (Dong and Benveniste, 2001, Farina et al., 2007). On their turn, IL-1 $\beta$  and TNF- $\alpha$  underlie the regulation of GJs and HCs in astrocytes. Overall, they reduce GJIC and open HCs (Orellana et al., 2009, Abudara et al., 2015). In fact, the former is disadvantageous for neurons as their survival heavily relies on cellular communication with astrocytes. Consequently, astrocytes can be considered as key players in infectious and neurodegenerative diseases in the central nervous system (Kielian, 2008, Quintanilla et al., 2012). Intracerebroventricular injection of LPS in rats upregulates Cx32 mRNA levels and decreases Cx43 expression in the hippocampus (Abbasian et al., 2012, Sayyah et al., 2012, Abbasian et al., 2013). When exposed to inflammatory agents, including cytokines, LPS and amyloid-β, astrocytes exhibit deterioration of GJIC (De Vuyst et al., 2007, Cruz et al., 2010, Hinkerohe et al., 2010, Liao et al., 2010, Orellana et al., 2010, Fruscione et al., 2011), but increased HC activity (Retamal et al., 2007, Orellana et al., 2010, Orellana et al., 2011). In

this respect, IL-1 $\beta$  inhibits GJ coupling and GJ conductance, along with a drop in Cx43 protein and mRNA expression in primary human fetal astrocytes (John *et al.*, 1999, Duffy *et al.*, 2000). Similarly, TNF- $\alpha$  treatment of primary rat astrocytes results in GJIC inhibition with simultaneous phosphorylation of Cx43 (Haghikia *et al.*, 2008b). NO is a mediator of inflammation by influencing phagocytes, leukocyte adhesion and smooth muscle cell dilation. As such, exposure of astrocytes to LPS leads to a dramatic augmentation of NOS (Liao *et al.*, 2010), thereby catalyzing the production of NO, and to a dose-dependent suppression of GJIC (Bolaños and Medina, 1996). This goes hand in hand with decreased Cx43 protein (Haghikia *et al.*, 2008a, Hinkerohe *et al.*, 2010) and mRNA expression (Liao *et al.*, 2010).

Production of pro-inflammatory mediators, like TNF- $\alpha$ , IL-1 $\beta$  and NO, is initiated upon exposure of astrocytes and microglia to *Staphylococcus aureus*, a Gram-positive bacterium able to cause inflammation in the brain. Recognition of peptidoglycan, the major cell wall product of *S. aureus*, in astrocytes and microglia occurs through Toll-like receptor 2 (Esen *et al.*, 2004). Activation of the latter influences the p38 mitogen-activated protein kinase pathway, which in turn reduces Cx43 mRNA and protein expression and abrogates GJIC (Zvalova *et al.*, 2004, Esen *et al.*, 2007). In contrast, upregulated Cx43 mRNA and protein levels are detected in primary microglia (Garg *et al.*, 2005). *Trypanosoma cruzi* and *Toxoplasma gondii*, both zoonotic protozoan parasites able to invade the central nervous system, cause loss of GJIC in astrocytes and leptomeningeal cells without affecting Cx43 expression or its posttranslational processing (Campos de Carvalho *et al.*, 1998, Kielian, 2008). Additionally, human immunodeficiency virus infection of astrocytes results in opening of Cx43-based HCs and triggers a slight reduction in astrocytic GJ coupling (Orellana *et al.*, 2014).

HCs at the blood-brain barrier have been linked to inflammation. In endothelial cells, dye uptake through HCs is induced when immortalized rat brain cells are exposed to conditioned medium harvested from LPS-activated microglia (Orellana *et al.*, 2009). Treatment of immortalized mouse endothelial cells with peptidoglycan, isolated from *S. epidermidis*, also activates Cx43-based HCs. This induces the release of ATP and results in the increased expression of Toll-like receptor 2, thereby potentiating the production of IL-6 (Robertson *et al.*, 2010). Moreover, the inflammatory stressor bradykinin induces HC-mediated calcium oscillations in microvascular brain endothelial cells and subsequent blood-brain barrier disruption (De Bock *et al.*, 2011). The endothelial cytoplasmic calcium concentration plays an important role in blood-brain barrier function, whereby an increase is associated with a dysfunctional barrier (De Bock *et al.*, 2013). After ischemia, HC opening results in an inability for endothelial cells to osmoregulate resulting in vessel leak within 2 hours and microvascular disorganization. Systemic delivery of Peptide5, reduced vascular leak (Danesh-Meyer *et al.*, 2012).

Following spinal cord injury in rats, accompanied by hemorrhage, damage and inflammation (Norenberg *et al.*, 2004), Cx43 protein and mRNA quantities are increased in astrocytes with no changes in the expression of Cx32 and Cx36 (Lee *et al.*, 2005). Fibroblast growth factor (FGF)-1, which is released in spinal cord injury, activates spinal astrocytes in culture leading to cell permeabilization, as evidenced by increased extracellular secretion of ATP and

cytosolic uptake of fluorescent tracers. As shown by the use of ATPase apyrase and by P2X7 receptor antagonists, the compromised cell membrane integrity is mediated, at least in part, by Cx43-based HCs (Garré *et al.*, 2010). In summary, interesting changes in Cx expression are observed in virtually all forms of inflammation related to the brain or spinal cord. Such changes may ameliorate or worsen outcomes of disease.

2.1.2 Roles of connexins and their channels in inflammation in the brain and **spinal cord**—Auto-immune encephalomyelitis experimentally evoked in  $Cx32^{-/-}$  mice results in an exacerbated clinical course with more pronounced demyelination and axonal loss despite a similar degree of inflammation and an overall milder loss of Cx47-based and Cx43-based GJs (Markoullis et al., 2012a). However, the susceptibility or severity of experimental auto-immune encephalomyelitis does not alter in astrocyte-specific Cx43<sup>fl/fl</sup>Cx30<sup>-/-</sup> mice (Lutz *et al.*, 2012). Treatment of astrocytes with a pro-inflammatory cytokine mixture consisting of TNF-a and IL-1ß stimulates Cx43-based HC activity (Froger et al., 2010). Interestingly, application of Gap26 and Gap27 or synthetic cannabinoid prevents cytokine-induced neurotoxicity. This demonstrates that inflammation-induced astroglial HC activation fulfills a critical function in neuronal death and suggests a neuroprotective role of Cx43-based blockade. This is substantiated by reduction in Cx43 expression upon treatment of spinal astrocytes with TNF- $\alpha$  and interferon (IFN)- $\gamma$ , which can be prevented by blocking c-jun terminal kinase (Zhang et al., 2013b) or ubiquitinproteasome (Zhang et al., 2015), both involved in apoptosis, neurodegeneration and cytokine production. Cx43 HCs play a major role in brain inflammation (Kim et al., 2016), and delivery of Cx43 HC-blocking peptides (O'Carroll et al., 2008) into the ventricles of the brain after ischemia in near-term sheep, a model for cerebral palsy, improves functional elektroretinography outcomes, reduces seizure and status epilepticus, give faster return to normal sleep cycling and promotes both oligodendrocyte and neuronal survival (Davidson et al., 2012). A similar result was obtained in a preterm sheep asphyxia study (Davidson et al., 2014). A recent study using astrocytic-specific Cx43<sup>fl/fl</sup> mice reveals a decline in ATPinduced inflammation, less manifested macrophage and microglia recruitment, and enhanced functional recovery following spinal cord injury (Huang et al., 2012). Spinal cord of rats treated with Cx43-antisense oligonucleotides or Cx43 HC-blocking mimetic peptides show reduced swelling, inflammation and tissue disruption after injury (Cronin et al., 2008, O'Carroll et al., 2013). Cytoplasmic calcium concentration is an important factor for determining the functional state of the blood-brain barrier. Bradykinin can trigger intracellular calcium oscillations in immortalized and primary brain endothelial cells. These effects are inhibited by blocking Cx-based channels using carbenoxolone, small interfering RNA-based silencing of endothelial Cx37 and Cx43, and Gap27 (De Bock et al., 2011).

#### 2.2 Heart

**2.2.1 Effects of inflammation on connexins and their channels in heart**—The predominant Cx species in cardiac tissue are Cx40, Cx43 and Cx45 (Table 1) (Delmar and Makita, 2012, Meens *et al.*, 2015). Cx40 can be found in atrial myocytes, the atrioventricular node, the His-bundle and ventricular conduction system (Gros and Jongsma, 1996, Severs *et al.*, 2004). Cx45 is mainly localized in the sinoatrial and atrioventricular nodes (Jansen *et al.*, 2010) and at the interface between the fast conducting pathway and the working

myocardium (Coppen et al., 1998), while Cx43 is most abundantly present in atrial and ventricular myocytes (Lampe and Lau, 2004, Michela et al., 2015). Most ventricular GJs composed of Cx43 gather at intercalated discs (Vozzi et al., 1999), often with larger junctional plaques at the disc periphery, and are rarely distributed to the lateral membranes of cardiomyocytes. The specific localization of Cx43 is essential for rapid propagation of action potentials (Del Ry et al., 2015, Michela et al., 2015). Emerging evidence has suggested novel roles of Cx43-based HCs in cardiac homeostasis, as unopposed HCs reside in the periphery of GJ plaques termed perinexus (Rhett and Gourdie, 2012). In contrast to GJIC, Cx43-based HCs between the cytosol and the extracellular area of cardiomyocytes may, when open, lead to swelling, cell dysfunction and cell death (Plotkin et al., 2002, Goodenough and Paul, 2003, Wang et al., 2013c). Cx43 mRNA levels are found to be dramatically and rapidly downregulated in rat heart after injection of LPS. Of note, TNF-a decreases Cx43 gene promoter activity in H9c2 myoblast cells (Fernandez-Cobo et al., 1999). Expression of transforming growth factor (TGF)- $\beta$ , driving cell growth, cell differentiation, apoptosis and cellular homeostasis, is increased during T. cruzi infection and regulates fibrosis and the parasite cell cycle. Exposure to TGF- $\beta$  induces disorganized GJ formation in non-infected cardiomyocytes, accompanied by punctate, diffuse and nonuniform Cx43 staining (Waghabi et al., 2009). Analogous experiments have been performed with infected patients and confirmed downregulation of Cx43 expression, altered distribution of cardiac GJ plaques and a significant reduction in the number and length of Cx43-positive GJ plaques inversely correlating with cardiomegaly and sepsis (Celes et al., 2007, Adesse et al., 2008, Waghabi et al., 2009, Carvalho et al., 2012).

#### 2.2.2 Roles of connexins and their channels in inflammation in heart—In a

recent set of studies, lipoxin A4, a bioactive product derived from arachidonic acid and a resolver of inflammation, showed protection of several organs against ischemia/reperfusion insults (Ye et al., 2011, Scully et al., 2012). In ischemia/reperfusion injury in rat, lowered levels of inflammatory cytokines, including IL-1 $\beta$ , IL-6, IL-8 and TNF- $\alpha$ , oxidative stress as well as increased quantities of Cx43 are measured after treatment with lipoxin A4. Moreover, lipoxin A4 preconditioning and postconditioning in myocardial ischemia/ reperfusion injury can attenuate metabolic disturbance in myocardium through upregulation of sodium/potassium ATPase expression, an important mediator in the maintenance of cardiac homeostasis (Zhao et al., 2013). Gap19 has been demonstrated to specifically inhibit Cx43-based HCs without affecting its corresponding GJs in cardiomyocytes (Wang et al., 2013c). Importantly, this peptide prevents metabolic inhibition-enhanced HC opening, protects cardiomyocytes against volume overload and cell death following ischemia/ reperfusion in vitro, and modestly decreases the infarct size after myocardial ischemia/ reperfusion in mouse (Wang et al., 2013c). Murine macrophages co-cultured with murine atrial myocyte-derived cells and subjected to mechanical stretch show macrophage migration and transient increases in extracellular ATP concentration. These effects are blocked by the GJ and HC-blocker carbenoxolone and the non-specific ATP signaling modifiers apyrase and pyridoxal-phosphate-6-azophenyl-2',4'-disulfonate (Oishi et al., 2012). This outcome can be reversed if cells are incubated with SB-431542, an inhibitor of TGF- $\beta$  receptor type I.

#### 2.3 Blood vessels

Effects of inflammation on connexins and their channels in blood 2.3.1 vessels-Cx37, Cx40, Cx43 and Cx45 are expressed in the vascular wall. Cx43, Cx37 and Cx40 are present in endothelial cells, of which their expression levels depend on the type of vessel and its position in the vascular tree (Meens et al., 2015). Cx43, Cx45, Cx37 and Cx40 can be found in smooth muscle cells (Table 1) (Scheckenbach et al., 2011). Lymphatic endothelial cells express Cx37, Cx43 and Cx47 (Meens et al., 2014). In all vascular cells, Cx proteins and their channels play an important role in the coordination of vascular responses. They drive the dynamic modulation of vascular resistance and blood flow to match different tissue oxygen requirements (Schmidt et al., 2008, Johnstone et al., 2009). Moreover, they participate in the development of lymphatic valves (Kanady et al., 2011, Sabine et al., 2012). Consequently, Cx proteins have also been described to be involved in pathological conditions of blood vessels, such as atherosclerosis (Pfenniger et al., 2013). The latter is a progressive disease characterized by the accumulation of macrophages, lymphocytes, smooth muscle cells and lipids in the vascular wall, and is tightly associated with inflammation. Cx37 is expressed in macrophage foam cells and monocytes, which are important mediators in the progression of atherosclerosis. ATP release through Cx37-based HCs is linked to inhibition of leukocyte adhesion, suggesting that these channels may control initiation of atherosclerotic plaque development (Wong et al., 2006). Both Cx37 and Cx40 productions are decreased in the endothelium of atherosclerotic plaques (Kwak et al., 2002, Yeh et al., 2003) and their expression is altered by oxidative stress, prothrombotic molecules and pro-inflammatory agents (Simon et al., 2004, Hou et al., 2008). This is supported by complete disappearance of Cx37 and Cx40 when human umbilical vein endothelial cells are stimulated with TNF-a (van Rijen et al., 1998). Furthermore, Cx43 expression is upregulated in experimental coronary atherosclerosis, especially in macrophage foam cells (Blackburn et al., 1995, Polacek et al., 1997, Kwak et al., 2002). Moreover, LPS-injected rats show enhanced Cx40 expression in the aorta with simultaneous increased levels of inflammatory markers, like C-reactive protein, and oxidative stress markers, including malondialdehyde. Omega-3 fatty acids negatively affect the expression of Cx40 in aortic tissue and suppress C-reactive protein and malondialdehyde production (Frimmel et al., 2014). LPS activates c-jun terminal kinases 1 and 2, p38 and extracellular signal-regulated kinases 1 and 2, yet it also abrogates GJ coupling in endothelial cells isolated from wild-type, Cx37<sup>-/-</sup> and Cx43<sup>G60S</sup> mutant mice (Bolon et al., 2007). Although the effects of inflammation on Cx expression and function may differ according to the vascular bed involved, treatment strategies targeting Cxs may improve disease outcome.

#### 2.3.2 Roles of connexins and their channels in inflammation in blood vessels

---Cx37 seems to protect against atherosclerosis since deletion of Cx37 accelerates atherogenesis in Cx37<sup>-/-</sup>/apolipoproteinE<sup>-/-</sup> mice. These animals show an increase in aortic lesions caused by enhanced monocyte and macrophage recruitment (Wong *et al.*, 2006). Shear stress, an essential feature of atherogenesis (Kwak *et al.*, 2014), applied to the same mouse model is found to increase the atherosclerotic plaque size in Cx37<sup>-/-</sup>/ apolipoproteinE<sup>-/-</sup> animals in comparison with apolipoproteinE<sup>-/-</sup> counterparts (Pfenniger *et al.*, 2015). When Cx37<sup>-/-</sup> monocytes or macrophages are introduced in hypercholesterolemic Cx37<sup>+/+</sup> mice, a higher amount of leukocytes is found in the atherosclerotic plaque,

suggesting a role of Cx37 in monocyte and macrophage function (Wong et al., 2006). Conversely, a polymorphism of Cx37 or blockage of Cx37-based HCs reduces the release of ATP out of the cells and increases their adhesion to substrates (Chanson and Kwak, 2007). Endothelial-specific  $Cx40^{-/-}$  mice show spontaneous atherosclerotic lesions in the aorta by promoting leukocyte adhesion through cluster of differentiation 73 (Chadjichristos et al., 2010). The latter fulfills enzymatic activities through the conversion of ATP to adenosine monophosphate and adenosine in immune cells (Chadjichristos et al., 2010, Antonioli et al., 2013). In contrast to the seemingly protective effects of Cx37 and Cx40, Cx43 rather acts in an atherogenic way. Indeed, low density lipoprotein receptor-/-/Cx43+/- mice fed a cholesterol-rich diet display reduced atherosclerosis in the thoraco-abdominal aorta and in the aortic roots in comparison with low density lipoprotein receptor-deficient mice. Specifically, smaller atherosclerotic plaques, fewer inflammatory cells and thicker fibrous caps are found (Kwak et al., 2003, Wong et al., 2003). Targeting the Cx43 microtubulebinding domain by JM2, a Cx43 mimetic peptide identical to a sequence of the C-terminal intracellular loop, results in a decrease in ATP release in cultured human endothelial cells and decreases the total inflammatory infiltrate in a rat model of inflammation (Calder et al., 2015), illustrating that targeting endothelial Cx43 might be a promising anti-inflammatory approach.

#### 2.4 Liver

**2.4.1** Effects of inflammation on connexins and their channels in liver—In liver, Cx32 and Cx26 are expressed by hepatocytes (Kyoi *et al.*, 1992, Ohkusa *et al.*, 1995, Iwata *et al.*, 1998, Radebold *et al.*, 2001). Non-parenchymal livers cells, including Kupffer cells, sinusoidal endothelial cells and stellate cells, produce Cx26 and Cx43 (González *et al.*, 2002, Eugenín *et al.*, 2007, Hernández-Guerra *et al.*, 2014). GJIC underlies critical hepatic functions, including xenobiotic biotransformation and plasma protein synthesis (Maes *et al.*, 2015b).

Upon injection of LPS in rodents, decreased Cx32 and Cx26 protein levels at the plasma membrane of hepatocytes are observed. This is reminiscent of what is observed in hepatitis patients in clinical settings (Correa et al., 2004). Additionally, Cx32 mRNA levels are diminished during the inflammatory response in liver, while Cx26 mRNA remains unchanged (De Maio et al., 2000). In primary hepatocyte cultures, IL-1β decreases Cx32 levels and GJIC becomes compromised by TNF-a, IL-1β and IL-6. Hepatic Cx26 mRNA is upregulated after exposure of cultured immortalized hepatocytes to IL-1, IL-6 and TNF-a (Temme et al., 1998). The same holds true for Cx43 protein and mRNA in primary stellate cells exposed to LPS or IL-1 $\beta$  (Fischer *et al.*, 2005). When treated with LPS and IFN- $\gamma$ , Kupffer cells increasingly express Cx43 in vitro and in vivo (Eugenín et al., 2007). Moreover, GJIC deteriorates in mice upon intoxication with acetaminophen, which triggers an inflammatory response, and is associated with a switch in mRNA and protein production from Cx32 and Cx26 to Cx43. The upregulation of Cx43 expression is due, at least in part, to de novo production by hepatocytes (Maes et al., 2016a). Likewise, Cx32 production is drastically downregulated upon acute-on-chronic liver failure in rats. At the same time, Cx43-positive spots appear in particular in the vicinity of inflamed areas (Balasubramaniyan et al., 2013).

2.4.2 Roles of connexins and their channels in inflammation in liver—Cx32 exerts a protective effect in experimental non-alcoholic steatohepatitis, a chronic liver disease associated with fat accumulation and inflammation (Willebrords et al., 2015), as based upon increased levels of inflammatory cytokines and more pronounced oxidative stress in Cx32 dominant negative transgenic (Cx32 Tg) rats (Sagawa et al., 2015). The role of Cx32 in liver injury is further investigated in Cx32<sup>-/-</sup> mice and Cx32 Tg rats treated with acetaminophen. Both amplification and alleviation of this toxicological process by Cx32 is described (Naiki-Ito et al., 2010, Igarashi et al., 2014, Maes et al., 2016b). Acetaminophen causes liver damage, inflammation and oxidative stress upon overdose. However, Cx32<sup>-/-</sup> mice display no differences in inflammation, cell death and oxidative stress in comparison with wild-type mice (Maes et al., 2016b). Cx43<sup>+/-</sup> mice tend to show increased liver cell death, inflammation and oxidative stress, suggesting that hepatic Cx43-based signaling may protect against acetaminophen-induced liver toxicity (Maes et al., 2016a). In rat liver lobules treated with thioacetamide, disappearance of Cx32 at the cell borders of hepatocytes is observed. In primary cultures of rat hepatocytes, IL-1ß causes the loss of Cx32. These effects are mitigated by a mitogen-activated protein kinase and p38 mitogen-activated protein inhibitor, respectively. This demonstrates the involvement of these signal transduction pathways in the regulation of Cx32 during the acute-phase response to IL-1 $\beta$ (Yamamoto et al., 2004).

#### 2.5 Stomach and intestine

At least 10 different Cx types are expressed in the intestinal tract. Cx26, Cx32, Cx36, Cx37, Cx40, Cx43, Cx45 and Cx57 are detected in the small intestine of several species, whereas Cx26, Cx31, Cx31.1, Cx32, Cx36, Cx40, Cx43 and Cx45 are present in the colon (Table 1) (Maes *et al.*, 2015a). The stomach produces 3 Cx species with Cx26 in epithelial cells and *lamina propria* of the fundus (Fiertak *et al.*, 1999, Radebold *et al.*, 2001, Liu *et al.*, 2010), Cx32 in the glandular regions, specifically in foveolar cells (Kyoi *et al.*, 1992, Uchida *et al.*, 1995, Radebold *et al.*, 2001) and Cx43 in circular muscle layers in gastric tissue (Seki and Komuro, 2002, Nishitani *et al.*, 2005). These Cx proteins have been linked with an array of gastrointestinal features including motility, gastric acid secretion and intestinal innate immune defense (Maes *et al.*, 2015a).

*Helicobacter pylori* colonizes the gastric mucosa and harms the stomach by several mechanisms, such as produced ammonia, proteases, vacuolating cytotoxin A, phospholipases and cytotoxin associated gene (Cag) A (Smoot, 1997). Indeed, CagA-positive *Helicobacter pylori* can cause gastritis, an inflammatory reaction of the stomach lining, and thereby abolish GJIC in cultured human gastric epithelial cells (Tao *et al.*, 2007, Xu *et al.*, 2011), while Cx43 expression is diminished in cultured human gastric carcinoma cells (Xu *et al.*, 2007). Likewise, in gastric lesions of *Helicobacter pylori*-infected patients, Cx32 and Cx43 levels are reduced, especially with the CagA-positive variant (Jia *et al.*, 2008, Xu *et al.*, 2008a, Xu *et al.*, 2008b). *Shigella flexneri*, a species of Gram-negative bacteria, causes inflammation by invading the colonic mucosa. This induces the opening of Cx26-based HCs through actin and phospholipase C, which allows extracellular release of ATP (Tran Van Nhieu *et al.*, 2003, Simpson *et al.*, 2013). ATP is also found to be an early alert response to infection with enteric pathogens that eventually promote inflammation of

the gut. In colonic epithelium in mouse models of intestinal inflammation, Cx43 expression is lost completely (Sedhom *et al.*, 2013). Similarly, Cx43 levels are decreased in enterocytes in a mouse model of necrotizing enterocolitis. In this case, the release of IFN- $\gamma$  suppresses GJIC by inducing the dephosphorylation and internalization of Cx43 (Leaphart *et al.*, 2007).

#### 2.6 Skin

Skin, the largest organ of the body that forms a highly complex and organized protective barrier against the external environment, is constituted of 3 major layers, namely the epidermis, the dermis and the hypodermis. As the blood supply of the skin is limited to the 2 latter layers, cell-to-cell communication is necessary to provide signals and nutrients to the outer skin layers. In skin, a plethora of Cx proteins is expressed, including Cx26, Cx30, Cx30.3, Cx31, Cx31.1, Cx32, Cx37, Cx40, Cx43 and Cx45. Keratinocytes mainly produce Cx26 and Cx43 (Richard, 2000), while human dermal fibroblasts contain Cx43 and Cx45 and low quantities of Cx40 (Table 1) (Levit and White, 2015). These Cx species influence the coordination of cell proliferation, migration and differentiation events, thus maintaining epidermal homeostasis (Martin and van Steensel, 2015).

Mutations that cause inflammatory skin disease show dysregulated HCs composed of Cx26, Cx30, Cx31, and Cx43, as evidenced by extracellular ATP leakage and excessive cytosolic influx of calcium (Levit and White, 2015). Cx26 mutations, producing leaky HCs and disturbing GJ formation, can cause a diversity of skin diseases of which keratitis-ichthyosisdeafness is accompanied by inflammation (Scott et al., 2012, Martin and van Steensel, 2015). During wound healing in rat and human, a process that involves inflammation, Cx26 and Cx30 levels are upregulated (Coutinho et al., 2003, Brandner et al., 2004, Sutcliffe et al., 2015). In addition, hyperproliferation occurs and wound healing is suppressed by persistent expression of Cx26 in mouse epidermis. Mechanistically, ectopic expression of Cx26 in keratinocytes results in increased ATP release, which delays epidermal barrier recovery and promotes an inflammatory response in resident immune cells (Djalilian et al., 2006). In contrast, Cx43 production is lost at wound sites and surrounding areas of the epidermis in rat (Goliger and Paul, 1995), mouse (Coutinho et al., 2003) and human (Neub et al., 2007), but continues to be expressed in diabetic wounds (Wang et al., 2007). Bacterial cell wall components differentially influence expression levels and opening of Cx26-based (Donnelly et al., 2012) and Cx43-based HCs (Robertson et al., 2010). In this respect, peptidoglycan isolated from S. aureus promotes open HCs states in a human keratinocyte cell line transfected with keratitis-ichthyosis-deafness-associated Cx26 constructs. Furthermore, peptidoglycan stimulates ATP release into the extracellular milieu and increases IL-6 levels in human cervical cancer HeLa cells and human keratinocyte HaCaT cells expressing keratitis-ichthyosis-deafness mutants (Donnelly et al., 2012). Gap27 accelerates wound healing and elevates cell proliferation in ex vivo models of wound healing (Evans and Leybaert, 2007, Wright et al., 2009, Pollok et al., 2011). Additionally, targeting Cx43 with ACT1, a peptide mimetic of the carboxyl-terminus of Cx43, accelerates fibroblast migration and proliferation, and wound reepithelialization in adults with chronic venous leg ulcers (Ghatnekar et al., 2015). Similar promising results were obtained with antisense oligonucleotides targeting Cx43, improve wound closure events (Martin, 2015). When aCT1, a peptide based on the carboxyl-terminus of Cx43 is applied in the skin, a decreased

inflammatory response, reduced area of scar progenitor tissue, and restoration of more normal dermal structure and mechanical strength is found (Ongstad *et al.*, 2013). Furthermore, it has been found that Cx43<sup>+/-</sup> mice show accelerated re-epithelialization and wound closure, increases proliferation and activation of dermal fibroblasts, and enhances the expression of extracellular matrix remodeling mediators (Cogliati *et al.*, 2015).

# 2.7 Kidney

In kidney, Cx26, Cx30.3, Cx31, Cx32, Cx37, Cx40, Cx43, Cx45 and Cx46 are expressed, of which Cx37, Cx40, Cx43 and Cx45 are present in renal vasculature (Hanner *et al.*, 2010, Abed *et al.*, 2014a). Cx43 is found in vascular endothelium, smooth muscle of larger vessels, glomerular epithelial cells, proximal tubular cells and glomerular endothelial cells (Table 1) (Hillis *et al.*, 1997b). GJs are involved in several physiological and pathological processes in kidney (Wagner and Kurtz, 2013). Indeed, maintaining normal renal hemodynamics requires regulation of renal vascular conductance, endothelium-derived vasodilatation and autoregulatory mechanisms, all which are controlled by Cx-based signaling (Wagner *et al.*, 2007, Wagner *et al.*, 2010).

There is growing evidence of an intimate relation between Cx expression and the occurrence of inflammation in the kidney (Scheckenbach et al., 2011, Abed et al., 2014a). Cx37 and Cx40 are hereby considered anti-inflammatory renal Cx members, while Cx43 acts in a proinflammatory way (Abed et al., 2014a, Abed et al., 2014b). Cx43 is strongly expressed by inflammatory cells, damaged tubular cells and interstitial cells and in the endothelium of peritubular and glomerular capillaries at the early stages of hypertensive nephropathy in mouse (Toubas et al., 2011). This pattern of Cx43 expression is very similar to that of intercellular adhesion molecule 1 and, to a lesser extent, of vascular cell adhesion molecule 1, both produced by renal endothelium in inflammatory conditions. Cx43 is therefore thought to be primarily implicated in tubule-interstitial inflammation (Hillis et al., 1997a). Treatment of normal rat kidney epithelial cells with LPS results both in downregulation (Gerl et al., 2014) and upregulation (Fernandez-Cobo et al., 1998) of Cx43 expression. In contrast, Cx37, which is abundantly produced in the renal cortex of healthy mice, is markedly decreased in experimental models of chronic kidney disease (Toubas et al., 2011). In a  $Cx43^{+/-}$  mouse model of chronic kidney disease, the renal cortex shows a decrease of cell adhesion markers leading to reduced monocyte infiltration and interstitial renal fibrosis. Interestingly, treatment with Cx43 antisense oligonucleotides improves renal function in mice suffering from chronic kidney disease. Furthermore, Cx43-specific blockage, by the Gap26 mimetic peptide, inhibits monocyte adhesion in activated endothelium and profibrotic pathways in tubular cells (Abed et al., 2014b).

### 2.8 Lung

Normal alveolar epithelium *in vivo* shows expression of Cx26, Cx32, Cx43 and Cx46 (Table 1) (Koval, 2002). Nevertheless, different Cx species, like Cx30 and Cx31, can be found in airway cell lines and airway cells in primary culture in non-differentiated and differentiated circumstances (Wiszniewski *et al.*, 2007). The continuous exposure to inhaled hostile factors makes lungs vulnerable to infection and inflammation. Therefore, proper tissue repair is of

utmost importance for maintaining lung homeostasis and relies on Cx-based signaling (Losa and Chanson, 2015).

Impairment of physiological Cx expression in lung is associated with an abnormal immune response in cystic fibrosis, a genetic disease in which lungs become clogged due to mucus secretion (Chanson et al., 2001, Huang et al., 2003a, Huang et al., 2003b). In bronchiolar epithelial cells, loss of Cx37 expression is linked to allergic airway disease and cytokine production by T-helper cells (Park et al., 2007). Cx43 is thought to be of importance for calcium signaling in lung tissue in inflammatory conditions, such as during acute lung injury and acute respiratory distress syndrome (MacCallum and Evans, 2005). Work with endothelial Cx43<sup>-/-</sup> mice demonstrates that Cx43 mediates calcium wave propagation that acts to amplify the inflammatory process (Parthasarathi et al., 2006). Calcium waves are known to underlie leukocyte rolling in the vascular surface and blocking of Cx43-based channels by peptides results in reduction of neutrophil adhesion to the endothelial cell surface in a mouse pneumocyte cell line (Parthasarathi et al., 2006, Sarieddine et al., 2009). This pro-inflammatory role of Cx43 has been confirmed in vascular endothelium-specific Cx43<sup>-/-</sup> mice, exhibiting a decrease in neutrophil recruitment after LPS-induced lung inflammation (Sarieddine et al., 2009). In cultured human pulmonary endothelial cells treated with LPS, mRNA and protein levels of Cx43 as well as GJIC are increased. The decrease of transendothelial resistance triggered by LPS hereby is attenuated following small interfering RNA-mediated suppression of Cx43 production (O'Donnell et al., 2014). Cx40 expression is diminished in lung of mouse and rabbit suffering from acute lung injury induced by intranasal instillation of LPS. However, no differences in pulmonary inflammation are noticed in  $Cx40^{+/-}$  mice in comparison with wild-type animals (Rignault *et* al., 2007). In a endothelial cell-specific  $Cx40^{-/-}$  mouse model, downregulated production of cluster of differentiation 73 is observed (Chadjichristos et al., 2010). The latter seems to play a protective role in acute lung injury by preventing leukocyte adhesion to the endothelium (Thompson et al., 2004, Volmer et al., 2006).

### 2.9 Eye

Cx family members identified in the eye include Cx26, Cx30, Cx30.2, Cx32, Cx36, Cx37, Cx43, Cx45, Cx46, Cx50 and Cx57 (Table 1). Cx43 is expressed in multiple cell types of the eyes, including astrocytes, Müller cells, microglia, retinal pigment epithelium and endothelial cells and supports many aspects of eye development and normal physiology, but is equally involved in corneal inflammation (Danesh-Meyer *et al.*, 2015).

Cultured human corneal fibroblasts exposed to TNF-α show reduced Cx43 expression. These effects are attenuated by an inhibitor of c-jun terminal kinase, suggesting the involvement of both the mitogen-activated protein kinase signaling pathway and Cx43 production in corneal inflammation (Kimura *et al.*, 2013). Incubation of retinal pigment epithelial cells with glucose induces accumulation of IL-6, IL-8 and TGF-β, and negatively affects Cx43 levels and GJIC (Losso *et al.*, 2010).

Intense light exposure in albino rats increases Cx36 levels in the inner plexiform layer and lowers Cx45 quantities in the light-damaged retina, while Cx43 production becomes intensified in the retinal pigment epithelium and the choroid. In the latter, Cx43 colocalizes

with indicators of nitration-related oxidative stress, like nitrotyrosine, inflammatory markers, such as cluster of differentiation 45, and ionized calcium-binding adaptor molecule-1 (Guo et al., 2014). A number of studies show that reducing Cx43 expression, or blocking channel function, in the eye can be beneficial. Treatment of corneal scrape wounds or laser ablations, mimicking photorefractive keratectomy, with Cx43 antisense oligonucleotides increases the rate of epithelial recovery, whilst significantly reducing oedema, myofibroblast differentiation and proliferation (Grupcheva et al., 2012). This outcome has been confirmed using a-carboxy terminus 1, a Cx43 mimetic peptide, that also reduces healing time and inflammation in a rat model of corneal inflammation (Moore et al., 2013). The Cx43 antisense oligonucleotides applied to humans with non-healing burns to the cornea under compassionate use promoted healing primarily by reducing inflammation and triggering vascular recovery to the limbus (Ormonde et al., 2012). Interestingly, injection of Cx43 antisense oligonucleotides in a rabbit model of glaucoma results in less myofibroblast production and reduced scarring (Deva et al., 2012). When used in patients with repeated trabeculectomy block owing to scarring, the Cx43 antisense oligonucleotides reduces scarring and resulted in long term maintenance of normal intraocular pressure (Becker et al., 2016). In a rat retina ischemia/reperfusion model, delivery of Peptide5, either systemically (Danesh-Meyer et al., 2012) or by intravitreal injection, considerably reduces vessel leak, significantly counteracts inflammation and promotes neuronal survival (Chen et al., 2013, Chen et al., 2015). Although Cx43 levels may be reduced in the diabetic retinal vessel bed (Tien et al., 2014, Tien et al., 2015), animal models and direct analysis of human donor tissues reveals very high levels of Cx43 associated with vessel endothelium, astrocytes and Müller cells near diabetic retinopathy lesions.

#### 2.10 Immune cells

The immune system provides a variety of defenses against PAMPs and DAMPs. This occurs through the establishment of physical and chemical barriers and the concerted actions of a wide spectrum of biochemical mediators and immune cells (Glass *et al.*, 2015). The expression and functional significance of several Cx family members, including Cx30.3, Cx32, Cx37, Cx40 and Cx43 (Table 1), have been documented in cells and tissues of the immune and lymphatic system (Oviedo-Orta and Howard Evans, 2004, Neijssen *et al.*, 2007). Cx43 is by far the most important Cx species in the immune system, being found in macrophages, neutrophils, dendritic cells, B-cells and T-cells (Glass *et al.*, 2015). Cx43 fulfills different functions, such as recruitment of neutrophils and T-cell activation (Glass *et al.*, 2015). Circulating monocytes contain Cx43 and its expression is increased upon LPS treatment. The latter, together with IFN- $\gamma$ , seems a prerequisite for establishing GJIC between cultured monocytes (Eugenín *et al.*, 2003). This suggests that Cx43 may be of importance in the formation of GJIC in macrophages (Alves *et al.*, 1996). Human tonsillar B-lymphocytes also express Cx43, which is upregulated *in vitro* after exposure to LPS (Oviedo-Orta *et al.*, 2000).

In the presence of GJ and HC inhibitors, such as  $18\beta$ -glycyrrhetinic acid or Cx mimetic peptides, cultured human lymphocytes produce less immunoglobulins M, G and A in response to phytohaemagglutinin activation. This indicates that inhibition of Cx43-based channels may result in disrupted communication between T-cells and B-cells or in

abrogation of immunoglobulin production (Oviedo-Orta *et al.*, 2001). Moreover, dye coupling is present between dendritic cells, suggesting that Cx43 is capable of forming functional GJs between these cells. Decreased dendritic cells activation and antigen presentation are observed when cells are treated with Gap27 following exposure to IFN- $\gamma$  and LPS (Matsue *et al.*, 2006). Using different Cx blocking agents, it has been found that polymorphonuclear leukocytes release ATP through Cx43-based HCs in a protein/ phosphatase-A-dependent manner. This is confirmed in polymorphonuclear leukocytes derived from Cx43<sup>fl/fl</sup> mice, whereby activated polymorphonuclear leukocytes display decreased extracellular ATP liberation (Eltzschig *et al.*, 2006). The release of ATP possibly plays a role in perpetuation of the inflammasome cycle in chronic disease conditions (Kim *et al.*, 2016).

#### 2.11 Other organs

Electrical and metabolic coupling between pancreatic  $\beta$ -cells is required for proper insulin secretion and effective glycemic control. In particular,  $\beta$ -cell-specific GJIC relies on Cx36-based GJs, which ensure orchestrated insulin release across islets (Cigliola *et al.*, 2013). Other Cx proteins identified in pancreas are Cx43, Cx45 and Cx32 (Charollais *et al.*, 1999) (Table 1). Cx32<sup>-/-</sup> mice exhibit a deleterious course of acute pancreatitis with increased necrosis, oedema and inflammation of the exocrine pancreas (Frossard *et al.*, 2003). In cerulein-induced pancreatitis, irsogladine, an enhancer of GJIC, lowers the severity of the disease, decreases serum and pancreatic amylase. This coincides with disappearance of Cx32 in the pancreatic acini (Ito *et al.*, 1997). This is not the case in a similar model in rat, where Cx32 mRNA and protein levels are both increased upon induction of pancreatitis with cerulein (Ogoshi *et al.*, 2002).

Myoblasts express several Cx proteins, of which Cx39, Cx40, Cx43 and Cx45 are present in developing myoblasts and injured adult skeletal muscle (Table 1) (Merrifield and Laird, 2015). Cx43 has been detected in prefusional C2C12 myoblasts (Constantin and Cronier, 2000) and in primary cultures, and drives the differentiation and regeneration of the skeletal muscle (Araya et al., 2005). Transient expression of Cx40 has been described in axial skeletal muscles of mouse embryos during myoblast fusion (Dahl et al., 1995). Other Cx species found in muscle include Cx39 and Cx45 (von Maltzahn et al., 2004, von Maltzahn et al., 2011). Denervation of fast skeletal muscle cells activates NF-xB and elevates mRNA levels of TNF- $\alpha$  and IL-1 $\beta$ , which clearly shows the onset of inflammation after denervation. These effects cannot be reproduced in Cx43<sup>fl/fl</sup>Cx45<sup>fl/fl</sup> mice. Interestingly, denervated myofibers display de novo formation of HCs composed of Cx39, Cx43, and Cx45 as well as increased expression of purinergic P2X7 receptors (Cea et al., 2013). Furthermore, when exposing cultured microvascular endothelial cells from murine skeletal muscle to LPS and hypoxia/reoxygenation, protein kinase A-specific phosphorylation of Cx40 is more reduced when compared to exposure to LPS or hypoxia/reoxygenation alone. This occurs through diminished electrical coupling between microvascular endothelial cells, which indicates phosphorylation-driven involvement of Cx40 in inflammation and ischemia/ reperfusion (Bolon et al., 2008).

Cx43 is the most abundantly expressed Cx species in bone, including osteocytes, osteoblasts and osteoclasts (Civitelli et al., 1993, Donahue et al., 1995). In addition, Cx45 and Cx46 are present in osteoblastic cells (Chaible et al., 2011, Plotkin and Bellido, 2013) and Cx37 production is found in osteoblasts, osteocytes and osteoclasts (Paic et al., 2009, Pacheco-Costa et al., 2014), while chondrocytes are positive for Cx43, Cx45, Cx32 and Cx46 (Mayan et al., 2013). Expression of Cx43 (Su et al., 1997, Kato et al., 2013), Cx32 (Yamaoka et al., 2000b), Cx40 and Cx45 (Yamaoka et al., 2002) has been demonstrated in cells of periodontal ligaments (Table 1). In cartilage in osteoarthritic shoulders, Cx43, collagen type I, and TNF- $\alpha$  levels are increased (Casagrande *et al.*, 2015). This also holds true for fibroblast-like synoviocytes exposed to LPS. Treatment of collagen-induced arthritic rats with small interfering RNA directed against Cx43 ameliorates paw swelling and reduces the manifestation of arthritis (Tsuchida et al., 2013). These findings indicate that suppression of Cx43 production has an anti-inflammatory outcome in rat and efficiently counteracts arthritis. Increasing Cx43 expression enhances the production of IL-1 and IL-6, and increases the secretion of collagenases into conditioned cell culture medium of cultured synovial fibroblasts. Conversely, knockdown of Cx43 production by small interfering RNA decreases expression of many of these inflammatory genes (Gupta et al., 2014).

# 3 Conclusions

Inflammatory diseases, such as multiple sclerosis, atherosclerosis, arthritis, gastritis and non-alcoholic steatohepatitis, affect millions of people worldwide. In the last decade, Cx proteins and their channels have been extensively studied in inflammatory conditions in a broad spectrum of tissues and cells. Collectively, these efforts show that Cx proteins play an important role in inflammatory processes in various organs, including brain, heart, blood vessels, liver, intestines, skin, lung and eye (Kwak et al., 2002, Sarieddine et al., 2009, Scheckenbach et al., 2011, Martin et al., 2014, Glass et al., 2015, Maes et al., 2015b, Meens et al., 2015). A number of experimental tools, such as genetically altered animals (Parthasarathi et al., 2006, Wong et al., 2006, Markoullis et al., 2012a, Abed et al., 2014b, Sagawa et al., 2015), small interfering RNA duplexes (Tsuchida et al., 2013, Gupta et al., 2014), HC blockers and GJ inhibitors (Matsue et al., 2006, Chanson and Kwak, 2007, O'Carroll et al., 2008, Deva et al., 2012, Wang et al., 2013c, Abed et al., 2014b), have allowed to gain a better insight into the molecular mechanisms underlying the involvement of Cx signaling in inflammation. Although to be considered with a lot of caution, genetic knockout experiments suggest that Cx43 seems to be a mainly pro-inflammatory Cx (Parthasarathi et al., 2006, Huang et al., 2012, Abed et al., 2014b), while Cx32 and Cx37 are rather anti-inflammatory (Table 3) (Frossard et al., 2003, Parthasarathi et al., 2006, Wong et al., 2006, Abed et al., 2014b, Sagawa et al., 2015). This is substantiated by studies that apply a variety of Cx-based channel blockers (Wright et al., 2009, Froger et al., 2010, Pollok et al., 2011, Deva et al., 2012, Wang et al., 2013c, Chever et al., 2014). Nevertheless, most of the presently used Cx-based channel blockers inhibit GJs and HCs (Bodendiek and Raman, 2010). Two potential exceptions include Gap19, which suppresses Cx43-based HC activity without affecting GJIC (Iyyathurai et al., 2013, Abudara et al., 2014), and Peptide5 (O'Carroll et al., 2008). Peptide5 has been successfully delivered directly and systemically in a number of animal models, and owing to its extracellular acting mode of action, can be

targeted to disease and injury sites. Gap19 needs to cross the plasma membrane to be effective and is more difficult to target, but its asset is the very selective HC blocking capability without reducing GJIC. Since Cx43-based HCs are often associated with pathological conditions, Gap19 and Peptide5, or similar extracellular acting peptides (Evans, 2015), could be of great value in the further investigation of the role of HCs in inflammation (Wang *et al.*, 2013c, Abed *et al.*, 2014b).

Overall, it can be concluded that Cxs and their channels play an important role in the inflammatory process and hence in a great number of highly prevalent diseases. This may provide opportunities for the search of novel drug targets and therapeutics for the clinical treatment of inflammatory diseases.

## Acknowledgements

This work was funded by grants of the European Research Council (Starting Grant 335476), the Fund for Scientific Research-Flanders (FWO grants G009514N and G010214N), the University Hospital of the Vrije Universiteit Brussel-Belgium ("Willy Gepts Fonds" UZ-VUB), the University of São Paulo-Brazil and the Foundation for Research Support of the State of São Paulo-Brazil (FAPESP SPEC grant 2013/50420-6) and the Swiss National Science Foundation (310030\_162579/1).

# Abbreviations

ATP	adenosine triphosphate
Cag	cytotoxin associated gene
CL	cytoplasmic loop
Cx	connexin
DAMPs	damage-associated molecular patterns
EL	extracellular loop
FGF	fibroblast growth factor
GJ(s)	gap junction(s)
GJIC	gap junctional intercellular communication
HC(s)	hemichannel(s)
IFN	interferon
IL	interleukin
LPS	lipopolysaccharide
NF	nuclear factor
NO(S)	nitric oxide (synthase)
PAMPs	pathogen-associated molecular patterns

TGF	transforming growth factor
ТМ	transmembrane domain
TNF	tumor necrosis factor

### References

- Abbasian M, Sayyah M, Babapour V, Mahdian R. Intracerebroventricular injection of lipopolysaccharide increases gene expression of connexin32 gap junction in rat hippocampus. Basic Clin Neurosci. 2013; 4:334–40. [PubMed: 25337366]
- Abbasian M, Sayyah M, Babapour V, Mahdian R, Choopani S, Kaviani B. Upregulation of connexins 30 and 32 gap junctions in rat hippocampus at transcription level by chronic central injection of lipopolysaccharide. Iran Biomed J. 2012; 16:127–32. [PubMed: 23023213]
- Abed A, Dussaule JC, Boffa JJ, Chatziantoniou C, Chadjichristos CE. Connexins in renal endothelial function and dysfunction. Cardiovasc Hematol Disord Drug Targets. 2014a; 14:15–21. [PubMed: 24720461]
- Abed A, Toubas J, Kavvadas P, Authier F, Cathelin D, Alfieri C, Boffa JJ, Dussaule JC, Chatziantoniou C, Chadjichristos CE. Targeting connexin 43 protects against the progression of experimental chronic kidney disease in mice. Kidney Int. 2014b; 86:768–79. [PubMed: 24850151]
- Abudara V, Bechberger J, Freitas-Andrade M, De Bock M, Wang N, Bultynck G, Naus CC, Leybaert L, Giaume C. The connexin43 mimetic peptide Gap19 inhibits hemichannels without altering gap junctional communication in astrocytes. Front Cell Neurosci. 2014; 8:306. [PubMed: 25374505]
- Abudara V, Roux L, Dallérac G, Matias I, Dulong J, Mothet JP, Rouach N, Giaume C. Activated microglia impairs neuroglial interaction by opening Cx43 hemichannels in hippocampal astrocytes. Glia. 2015; 63:795–811. [PubMed: 25643695]
- Adesse D, Garzoni LR, Huang H, Tanowitz HB, De Nazareth Meirelles M, Spray DC. Trypanosoma cruzi induces changes in cardiac connexin43 expression. Microbes Infect. 2008; 10:21–8. [PubMed: 18068391]
- Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell. 2006; 124:783–801. [PubMed: 16497588]
- Alstrom JS, Stroemlund LW, Nielsen MS, Macaulay N. Protein kinase C-dependent regulation of connexin43 gap junctions and hemichannels. Biochem Soc Trans. 2015; 43:519–23. [PubMed: 26009201]
- Altevogt BM, Kleopa KA, Postma FR, Scherer SS, Paul DL. Connexin29 is uniquely distributed within myelinating glial cells of the central and peripheral nervous systems. J Neurosci. 2002; 22:6458–70. [PubMed: 12151525]
- Alves LA, Coutinho-Silva R, Persechini PM, Spray DC, Savino W, Campos De Carvalho AC. Are there functional gap junctions or junctional hemichannels in macrophages? Blood. 1996; 88:328– 34. [PubMed: 8704191]
- Antonioli L, Pacher P, Vizi ES, Haskó G. CD39 and CD73 in immunity and inflammation. Trends Mol Med. 2013; 19:355–67. [PubMed: 23601906]
- Araya R, Eckardt D, Maxeiner S, Krüger O, Theis M, Willecke K, Sáez JC. Expression of connexins during differentiation and regeneration of skeletal muscle: functional relevance of connexin43. J Cell Sci. 2005; 118:27–37. [PubMed: 15601660]
- Arensbak B, Mikkelsen HB, Gustafsson F, Christensen T, Holstein-Rathlou NH. Expression of connexin 37, 40, and 43 mRNA and protein in renal preglomerular arterioles. Histochem Cell Biol. 2001; 115:479–87. [PubMed: 11455448]
- Balasubramaniyan V, Dhar DK, Warner AE, Vivien Li WY, Amiri AF, Bright B, Mookerjee RP, Davies NA, Becker DL, Jalan R. Importance of Connexin-43 based gap junction in cirrhosis and acute-onchronic liver failure. J Hepatol. 2013; 58:1194–200. [PubMed: 23376361]
- Basu R, Banerjee K, Bose A, Das Sarma J. Mouse Hepatitis Virus infection remodels Connexin43 mediated gap junction intercellular communication both in vitro and in vivo. J Virol. 2015

- Becker DL, Phillips AR, Duft BJ, Kim Y, Green CR. Translating connexin biology into therapeutics. Semin Cell Dev Biol. 2016; 50:49–58. [PubMed: 26688335]
- Berthoud VM, Minogue PJ, Osmolak P, Snabb JI, Beyer EC. Roles and regulation of lens epithelial cell connexins. FEBS Lett. 2014; 588:1297–303. [PubMed: 24434541]
- Beyer EC, Steinberg TH. Evidence that the gap junction protein connexin-43 is the ATP-induced pore of mouse macrophages. J Biol Chem. 1991; 266:7971–4. [PubMed: 1708769]
- Blackburn JP, Peters NS, Yeh HI, Rothery S, Green CR, Severs NJ. Upregulation of connexin43 gap junctions during early stages of human coronary atherosclerosis. Arterioscler Thromb Vasc Biol. 1995; 15:1219–28. [PubMed: 7627716]
- Bodendiek SB, Raman G. Connexin modulators and their potential targets under the magnifying glass. Curr Med Chem. 2010; 17:4191–230. [PubMed: 20939816]
- Bolaños JP, Medina JM. Induction of nitric oxide synthase inhibits gap junction permeability in cultured rat astrocytes. J Neurochem. 1996; 66:2091–9. [PubMed: 8780040]
- Bolon ML, Kidder GM, Simon AM, Tyml K. Lipopolysaccharide reduces electrical coupling in microvascular endothelial cells by targeting connexin40 in a tyrosine-, ERK1/2-, PKA-, and PKCdependent manner. J Cell Physiol. 2007; 211:159–66. [PubMed: 17149706]
- Bolon ML, Peng T, Kidder GM, Tyml K. Lipopolysaccharide plus hypoxia and reoxygenation synergistically reduce electrical coupling between microvascular endothelial cells by dephosphorylating connexin40. J Cell Physiol. 2008; 217:350–9. [PubMed: 18521823]
- Brandner JM, Houdek P, Hüsing B, Kaiser C, Moll I. Connexins 26, 30, and 43: differences among spontaneous, chronic, and accelerated human wound healing. J Invest Dermatol. 2004; 122:1310– 20. [PubMed: 15140236]
- Brisset AC, Isakson BE, Kwak BR. Connexins in vascular physiology and pathology. Antioxid Redox Signal. 2009; 11:267–82. [PubMed: 18834327]
- Calder BW, Matthew Rhett J, Bainbridge H, Fann SA, Gourdie RG, Yost MJ. Inhibition of connexin 43 hemichannel-mediated ATP release attenuates early inflammation during the foreign body response. Tissue Eng Part A. 2015; 21:1752–62. [PubMed: 25760687]
- Campos De Carvalho AC, Roy C, Hertzberg EL, Tanowitz HB, Kessler JA, Weiss LM, Wittner M, Dermietzel R, Gao Y, Spray DC. Gap junction disappearance in astrocytes and leptomeningeal cells as a consequence of protozoan infection. Brain Res. 1998; 790:304–14. [PubMed: 9593958]
- Carvalho CM, Silverio JC, Da Silva AA, Pereira IR, Coelho JM, Britto CC, Moreira OC, Marchevsky RS, Xavier SS, Gazzinelli RT, Da Glória Bonecini-Almeida M, et al. Inducible nitric oxide synthase in heart tissue and nitric oxide in serum of Trypanosoma cruzi-infected rhesus monkeys: association with heart injury. PLoS Negl Trop Dis. 2012; 6:e1644. [PubMed: 22590660]
- Casagrande D, Stains JP, Murthi AM. Identification of shoulder osteoarthritis biomarkers: comparison between shoulders with and without osteoarthritis. J Shoulder Elbow Surg. 2015; 24:382–90. [PubMed: 25595362]
- Cea LA, Cisterna BA, Puebla C, Frank M, Figueroa XF, Cardozo C, Willecke K, Latorre R, Sáez JC. De novo expression of connexin hemichannels in denervated fast skeletal muscles leads to atrophy. Proc Natl Acad Sci U S A. 2013; 110:16229–34. [PubMed: 24043768]
- Celes MR, Torres-Dueñas D, Alves-Filho JC, Duarte DB, Cunha FQ, Rossi MA. Reduction of gap and adherens junction proteins and intercalated disc structural remodeling in the hearts of mice submitted to severe cecal ligation and puncture sepsis. Crit Care Med. 2007; 35:2176–85. [PubMed: 17855834]
- Cepeda C, Chang JW, Owens GC, Huynh MN, Chen JY, Tran C, Vinters HV, Levine MS, Mathern GW. In Rasmussen encephalitis, hemichannels associated with microglial activation are linked to cortical pyramidal neuron coupling: a possible mechanism for cellular hyperexcitability. CNS Neurosci Ther. 2015; 21:152–63. [PubMed: 25438677]
- Chadjichristos CE, Scheckenbach KE, Van Veen TA, Richani Sarieddine MZ, De Wit C, Yang Z, Roth I, Bacchetta M, Viswambharan H, Foglia B, Dudez T, et al. Endothelial-specific deletion of connexin40 promotes atherosclerosis by increasing CD73-dependent leukocyte adhesion. Circulation. 2010; 121:123–31. [PubMed: 20026782]

- Chaible LM, Sanches DS, Cogliati B, Mennecier G, Dagli ML. Delayed osteoblastic differentiation and bone development in Cx43 knockout mice. Toxicol Pathol. 2011; 39:1046–55. [PubMed: 21934140]
- Chandrasekhar A, Bera AK. Hemichannels: permeants and their effect on development, physiology and death. Cell Biochem Funct. 2012; 30:89–100. [PubMed: 22392438]
- Chanson M, Berclaz PY, Scerri I, Dudez T, Wernke-Dollries K, Pizurki L, Pavirani A, Fiedler MA, Suter S. Regulation of gap junctional communication by a pro-inflammatory cytokine in cystic fibrosis transmembrane conductance regulator-expressing but not cystic fibrosis airway cells. Am J Pathol. 2001; 158:1775–84. [PubMed: 11337375]
- Chanson M, Derouette JP, Roth I, Foglia B, Scerri I, Dudez T, Kwak BR. Gap junctional communication in tissue inflammation and repair. Biochim Biophys Acta. 2005; 1711:197–207. [PubMed: 15955304]
- Chanson M, Kwak BR. Connexin37: a potential modifier gene of inflammatory disease. J Mol Med (Berl). 2007; 85:787–95. [PubMed: 17318613]
- Charollais A, Serre V, Mock C, Cogne F, Bosco D, Meda P. Loss of alpha 1 connexin does not alter the prenatal differentiation of pancreatic beta cells and leads to the identification of another islet cell connexin. Dev Genet. 1999; 24:13–26. [PubMed: 10079507]
- Chen GY, Nuñez G. Sterile inflammation: sensing and reacting to damage. Nat Rev Immunol. 2010; 10:826–37. [PubMed: 21088683]
- Chen YS, Green CR, Teague R, Perrett J, Danesh-Meyer HV, Toth I, Rupenthal ID. Intravitreal injection of lipoamino acid-modified connexin43 mimetic peptide enhances neuroprotection after retinal ischemia. Drug Deliv Transl Res. 2015; 5:480–8. [PubMed: 26238242]
- Chen YS, Toth I, Danesh-Meyer HV, Green CR, Rupenthal ID. Cytotoxicity and vitreous stability of chemically modified connexin43 mimetic peptides for the treatment of optic neuropathy. J Pharm Sci. 2013; 102:2322–31. [PubMed: 23696181]
- Chever O, Lee CY, Rouach N. Astroglial connexin43 hemichannels tune basal excitatory synaptic transmission. J Neurosci. 2014; 34:11228–32. [PubMed: 25143604]
- Churko JM, Laird DW. Gap junction remodeling in skin repair following wounding and disease. Physiology (Bethesda). 2013; 28:190–8. [PubMed: 23636264]
- Cigliola V, Chellakudam V, Arabieter W, Meda P. Connexins and β-cell functions. Diabetes Res Clin Pract. 2013; 99:250–9. [PubMed: 23176806]
- Civitelli R, Beyer EC, Warlow PM, Robertson AJ, Geist ST, Steinberg TH. Connexin43 mediates direct intercellular communication in human osteoblastic cell networks. J Clin Invest. 1993; 91:1888–96. [PubMed: 8387535]
- Clair C, Combettes L, Pierre F, Sansonetti P, Tran Van Nhieu G. Extracellular-loop peptide antibodies reveal a predominant hemichannel organization of connexins in polarized intestinal cells. Exp Cell Res. 2008; 314:1250–65. [PubMed: 18267319]
- Cogliati B, Vinken M, Silva TC, Araújo CM, Aloia TP, Chaible LM, Mori CM, Dagli ML. Connexin 43 deficiency accelerates skin wound healing and extracellular matrix remodeling in mice. J Dermatol Sci. 2015; 79:50–6. [PubMed: 25900674]
- Constantin B, Cronier L. Involvement of gap junctional communication in myogenesis. Int Rev Cytol. 2000; 196:1–65. [PubMed: 10730212]
- Coppen SR, Dupont E, Rothery S, Severs NJ. Connexin45 expression is preferentially associated with the ventricular conduction system in mouse and rat heart. Circ Res. 1998; 82:232–43. [PubMed: 9468194]
- Correa PR, Guerra MT, Leite MF, Spray DC, Nathanson MH. Endotoxin unmasks the role of gap junctions in the liver. Biochem Biophys Res Commun. 2004; 322:718–26. [PubMed: 15336523]
- Cottrell GT, Burt JM. Functional consequences of heterogeneous gap junction channel formation and its influence in health and disease. Biochim Biophys Acta. 2005; 1711:126–41. [PubMed: 15955298]
- Cousins HM, Edwards FR, Hickey H, Hill CE, Hirst GD. Electrical coupling between the myenteric interstitial cells of Cajal and adjacent muscle layers in the guinea-pig gastric antrum. J Physiol. 2003; 550:829–44. [PubMed: 12844505]

- Coutinho P, Qiu C, Frank S, Tamber K, Becker D. Dynamic changes in connexin expression correlate with key events in the wound healing process. Cell Biol Int. 2003; 27:525–41. [PubMed: 12842092]
- Cronin M, Anderson PN, Cook JE, Green CR, Becker DL. Blocking connexin43 expression reduces inflammation and improves functional recovery after spinal cord injury. Mol Cell Neurosci. 2008; 39:152–60. [PubMed: 18617007]
- Cruz NF, Ball KK, Dienel GA. Astrocytic gap junctional communication is reduced in amyloid-βtreated cultured astrocytes, but not in Alzheimer's disease transgenic mice. ASN Neuro. 2010; 2:e00041. [PubMed: 20730033]
- Dahl E, Winterhager E, Traub O, Willecke K. Expression of gap junction genes, connexin40 and connexin43, during fetal mouse development. Anat Embryol (Berl). 1995; 191:267–78. [PubMed: 7771689]
- Danesh-Meyer HV, Kerr NM, Zhang J, Eady EK, O'carroll SJ, Nicholson LF, Johnson CS, Green CR. Connexin43 mimetic peptide reduces vascular leak and retinal ganglion cell death following retinal ischaemia. Brain. 2012; 135:506–20. [PubMed: 22345088]
- Danesh-Meyer HV, Zhang J, Acosta ML, Rupenthal ID, Green CR. Connexin43 in retinal injury and disease. Prog Retin Eye Res. 2015
- Davidson JO, Drury PP, Green CR, Nicholson LF, Bennet L, Gunn AJ. Connexin hemichannel blockade is neuroprotective after asphyxia in preterm fetal sheep. PLoS One. 2014; 9:e96558. [PubMed: 24865217]
- Davidson JO, Green CR, Nicholson LF, O'carroll SJ, Fraser M, Bennet L, Gunn AJ. Connexin hemichannel blockade improves outcomes in a model of fetal ischemia. Ann Neurol. 2012; 71:121–32. [PubMed: 22275258]
- De Bock M, Culot M, Wang N, Bol M, Decrock E, De Vuyst E, Da Costa A, Dauwe I, Vinken M, Simon AM, Rogiers V, et al. Connexin channels provide a target to manipulate brain endothelial calcium dynamics and blood-brain barrier permeability. J Cereb Blood Flow Metab. 2011; 31:1942–57. [PubMed: 21654699]
- De Bock M, Vandenbroucke RE, Decrock E, Culot M, Cecchelli R, Leybaert L. A new angle on blood-CNS interfaces: a role for connexins? FEBS Lett. 2014; 588:1259–70. [PubMed: 24631535]
- De Bock M, Wang N, Decrock E, Bol M, Gadicherla AK, Culot M, Cecchelli R, Bultynck G, Leybaert L. Endothelial calcium dynamics, connexin channels and blood-brain barrier function. Prog Neurobiol. 2013; 108:1–20. [PubMed: 23851106]
- De Bock M, Wang N, Decrock E, Bultynck G, Leybaert L. Intracellular Cleavage of the Cx43 C-Terminal Domain by Matrix-Metalloproteases: A Novel Contributor to Inflammation? Mediators Inflamm. 2015; 2015:257471. [PubMed: 26424967]
- De Maio A, Gingalewski C, Theodorakis NG, Clemens MG. Interruption of hepatic gap junctional communication in the rat during inflammation induced by bacterial lipopolysaccharide. Shock. 2000; 14:53–9. [PubMed: 10909894]
- De Vuyst E, Decrock E, Cabooter L, Dubyak GR, Naus CC, Evans WH, Leybaert L. Intracellular calcium changes trigger connexin 32 hemichannel opening. EMBO J. 2006; 25:34–44. [PubMed: 16341088]
- De Vuyst E, Decrock E, De Bock M, Yamasaki H, Naus CC, Evans WH, Leybaert L. Connexin hemichannels and gap junction channels are differentially influenced by lipopolysaccharide and basic fibroblast growth factor. Mol Biol Cell. 2007; 18:34–46. [PubMed: 17079735]
- Decrock E, Vinken M, De Vuyst E, Krysko DV, D'herde K, Vanhaecke T, Vandenabeele P, Rogiers V, Leybaert L. Connexin-related signaling in cell death: to live or let die? Cell Death Differ. 2009; 16:524–36. [PubMed: 19197295]
- Del Ry S, Moscato S, Bianchi F, Morales MA, Dolfi A, Burchielli S, Cabiati M, Mattii L. Altered expression of connexin 43 and related molecular partners in a pig model of left ventricular dysfunction with and without dipyrydamole therapy. Pharmacol Res. 2015; 95–96:92–101.
- Delmar M, Makita N. Cardiac connexins, mutations and arrhythmias. Curr Opin Cardiol. 2012; 27:236–41. [PubMed: 22382502]

- Dermietzel R, Gao Y, Scemes E, Vieira D, Urban M, Kremer M, Bennett MV, Spray DC. Connexin43 null mice reveal that astrocytes express multiple connexins. Brain Res Brain Res Rev. 2000; 32:45–56. [PubMed: 10751656]
- Dermietzel R, Hertberg EL, Kessler JA, Spray DC. Gap junctions between cultured astrocytes: immunocytochemical, molecular, and electrophysiological analysis. J Neurosci. 1991; 11:1421– 32. [PubMed: 1851221]
- Dermietzel R, Traub O, Hwang TK, Beyer E, Bennett MV, Spray DC, Willecke K. Differential expression of three gap junction proteins in developing and mature brain tissues. Proc Natl Acad Sci U S A. 1989; 86:10148–52. [PubMed: 2557621]
- Deva NC, Zhang J, Green CR, Danesh-Meyer HV. Connexin43 modulation inhibits scarring in a rabbit eye glaucoma trabeculectomy model. Inflammation. 2012; 35:1276–86. [PubMed: 22427153]
- Di WL, Rugg EL, Leigh IM, Kelsell DP. Multiple epidermal connexins are expressed in different keratinocyte subpopulations including connexin 31. J Invest Dermatol. 2001; 117:958–64. [PubMed: 11676838]
- Djalilian AR, Mcgaughey D, Patel S, Seo EY, Yang C, Cheng J, Tomic M, Sinha S, Ishida-Yamamoto A, Segre JA. Connexin 26 regulates epidermal barrier and wound remodeling and promotes psoriasiform response. J Clin Invest. 2006; 116:1243–53. [PubMed: 16628254]
- Donahue HJ, Mcleod KJ, Rubin CT, Andersen J, Grine EA, Hertzberg EL, Brink PR. Cell-to-cell communication in osteoblastic networks: cell line-dependent hormonal regulation of gap junction function. J Bone Miner Res. 1995; 10:881–9. [PubMed: 7572312]
- Dong Y, Benveniste EN. Immune function of astrocytes. Glia. 2001; 36:180-90. [PubMed: 11596126]
- Donnelly S, English G, De Zwart-Storm EA, Lang S, Van Steensel MA, Martin PE. Differential susceptibility of Cx26 mutations associated with epidermal dysplasias to peptidoglycan derived from Staphylococcus aureus and Staphylococcus epidermidis. Exp Dermatol. 2012; 21:592–8. [PubMed: 22643125]
- Duffy HS, John GR, Lee SC, Brosnan CF, Spray DC. Reciprocal regulation of the junctional proteins claudin-1 and connexin43 by interleukin-1beta in primary human fetal astrocytes. J Neurosci. 2000; 20:RC114. [PubMed: 11090614]
- Eltzschig HK, Eckle T, Mager A, Küper N, Karcher C, Weissmüller T, Boengler K, Schulz R, Robson SC, Colgan SP. ATP release from activated neutrophils occurs via connexin 43 and modulates adenosine-dependent endothelial cell function. Circ Res. 2006; 99:1100–8. [PubMed: 17038639]
- Esen N, Shuffield D, Syed MM, Kielian T. Modulation of connexin expression and gap junction communication in astrocytes by the gram-positive bacterium S. aureus. Glia. 2007; 55:104–17. [PubMed: 17029244]
- Esen N, Tanga FY, Deleo JA, Kielian T. Toll-like receptor 2 (TLR2) mediates astrocyte activation in response to the Gram-positive bacterium Staphylococcus aureus. J Neurochem. 2004; 88:746–58. [PubMed: 14720224]
- Eugenín EA, Brañes MC, Berman JW, Sáez JC. TNF-alpha plus IFN-gamma induce connexin43 expression and formation of gap junctions between human monocytes/macrophages that enhance physiological responses. J Immunol. 2003; 170:1320–8. [PubMed: 12538692]
- Eugenín EA, Eckardt D, Theis M, Willecke K, Bennett MV, Saez JC. Microglia at brain stab wounds express connexin 43 and in vitro form functional gap junctions after treatment with interferongamma and tumor necrosis factor-alpha. Proc Natl Acad Sci U S A. 2001; 98:4190–5. [PubMed: 11259646]
- Eugenín EA, González HE, Sánchez HA, Brañes MC, Sáez JC. Inflammatory conditions induce gap junctional communication between rat Kupffer cells both in vivo and in vitro. Cell Immunol. 2007; 247:103–10. [PubMed: 17900549]
- Evans WH. Cell communication across gap junctions: a historical perspective and current developments. Biochem Soc Trans. 2015; 43:450–9. [PubMed: 26009190]
- Evans WH, Leybaert L. Mimetic peptides as blockers of connexin channel-facilitated intercellular communication. Cell Commun Adhes. 2007; 14:265–73. [PubMed: 18392994]
- Farina C, Aloisi F, Meinl E. Astrocytes are active players in cerebral innate immunity. Trends Immunol. 2007; 28:138–45. [PubMed: 17276138]

- Fernandez-Cobo M, Gingalewski C, De Maio A. Expression of the connexin 43 gene is increased in the kidneys and the lungs of rats injected with bacterial lipopolysaccharide. Shock. 1998; 10:97– 102. [PubMed: 9721975]
- Fernandez-Cobo M, Gingalewski C, Drujan D, De Maio A. Downregulation of connexin 43 gene expression in rat heart during inflammation. The role of tumour necrosis factor. Cytokine. 1999; 11:216–24. [PubMed: 10209069]
- Fiertak A, Semik D, Kilarski WM. Immunohistochemical analysis of connexin26 and 43 expression in the mouse alimentary tract. Folia Biol (Krakow). 1999; 47:5–11. [PubMed: 10723935]
- Filippov MA, Hormuzdi SG, Fuchs EC, Monyer H. A reporter allele for investigating connexin 26 gene expression in the mouse brain. Eur J Neurosci. 2003; 18:3183–92. [PubMed: 14686892]
- Fink C, Hembes T, Brehm R, Weigel R, Heeb C, Pfarrer C, Bergmann M, Kressin M. Specific localisation of gap junction protein connexin 32 in the gastric mucosa of horses. Histochem Cell Biol. 2006; 125:307–13. [PubMed: 16205941]
- Fischer R, Reinehr R, Lu TP, Schönicke A, Warskulat U, Dienes HP, Häussinger D. Intercellular communication via gap junctions in activated rat hepatic stellate cells. Gastroenterology. 2005; 128:433–48. [PubMed: 15685554]
- Frimmel K, Vlkovicova J, Sotnikova R, Navarova J, Bernatova I, Okruhlicova L. The effect of omega-3 fatty acids on expression of connexin-40 in Wistar rat aorta after lipopolysaccharide administration. J Physiol Pharmacol. 2014; 65:83–94. [PubMed: 24622833]
- Frinchi M, Di Liberto V, Turimella S, D'antoni F, Theis M, Belluardo N, Mudò G. Connexin36 (Cx36) expression and protein detection in the mouse carotid body and myenteric plexus. Acta Histochem. 2013; 115:252–6. [PubMed: 22897942]
- Froger N, Orellana JA, Calvo CF, Amigou E, Kozoriz MG, Naus CC, Sáez JC, Giaume C. Inhibition of cytokine-induced connexin43 hemichannel activity in astrocytes is neuroprotective. Mol Cell Neurosci. 2010; 45:37–46. [PubMed: 20684043]
- Froger N, Orellana JA, Cohen-Salmon M, Ezan P, Amigou E, Sáez JC, Giaume C. Cannabinoids prevent the opposite regulation of astroglial connexin43 hemichannels and gap junction channels induced by pro-inflammatory treatments. J Neurochem. 2009; 111:1383–97. [PubMed: 20050288]
- Frossard JL, Rubbia-Brandt L, Wallig MA, Benathan M, Ott T, Morel P, Hadengue A, Suter S, Willecke K, Chanson M. Severe acute pancreatitis and reduced acinar cell apoptosis in the exocrine pancreas of mice deficient for the Cx32 gene. Gastroenterology. 2003; 124:481–93. [PubMed: 12557153]
- Fruscione F, Scarfì S, Ferraris C, Bruzzone S, Benvenuto F, Guida L, Uccelli A, Salis A, Usai C, Jacchetti E, Ilengo C, et al. Regulation of human mesenchymal stem cell functions by an autocrine loop involving NAD+ release and P2Y11-mediated signaling. Stem Cells Dev. 2011; 20:1183–98. [PubMed: 20964598]
- Garg S, Md Syed M, Kielian T. Staphylococcus aureus-derived peptidoglycan induces Cx43 expression and functional gap junction intercellular communication in microglia. J Neurochem. 2005; 95:475–83. [PubMed: 16190870]
- Garré JM, Retamal MA, Cassina P, Barbeito L, Bukauskas FF, Sáez JC, Bennett MV, Abudara V. FGF-1 induces ATP release from spinal astrocytes in culture and opens pannexin and connexin hemichannels. Proc Natl Acad Sci U S A. 2010; 107:22659–64. [PubMed: 21148774]
- Gerl M, Kurt B, Kurtz A, Wagner C. Connexin 43 is not essential for the control of renin synthesis and secretion. Pflugers Arch. 2014; 466:1003–9. [PubMed: 24062052]
- Ghatnekar GS, Grek CL, Armstrong DG, Desai SC, Gourdie RG. The effect of a connexin43-based Peptide on the healing of chronic venous leg ulcers: a multicenter, randomized trial. J Invest Dermatol. 2015; 135:289–98. [PubMed: 25072595]
- Giaume C, Theis M. Pharmacological and genetic approaches to study connexin-mediated channels in glial cells of the central nervous system. Brain Res Rev. 2010; 63:160–76. [PubMed: 19963007]
- Glass AM, Snyder EG, Taffet SM. Connexins and pannexins in the immune system and lymphatic organs. Cell Mol Life Sci. 2015; 72:2899–910. [PubMed: 26100515]
- Goliger JA, Paul DL. Wounding alters epidermal connexin expression and gap junction-mediated intercellular communication. Mol Biol Cell. 1995; 6:1491–501. [PubMed: 8589451]

- González HE, Eugenín EA, Garcés G, Solís N, Pizarro M, Accatino L, Sáez JC. Regulation of hepatic connexins in cholestasis: possible involvement of Kupffer cells and inflammatory mediators. Am J Physiol Gastrointest Liver Physiol. 2002; 282:G991–G1001. [PubMed: 12016124]
- Goodenough DA, Paul DL. Beyond the gap: functions of unpaired connexon channels. Nat Rev Mol Cell Biol. 2003; 4:285–94. [PubMed: 12671651]
- Gros DB, Jongsma HJ. Connexins in mammalian heart function. Bioessays. 1996; 18:719–30. [PubMed: 8831288]
- Grupcheva CN, Laux WT, Rupenthal ID, Mcghee J, Mcghee CN, Green CR. Improved corneal wound healing through modulation of gap junction communication using connexin43-specific antisense oligodeoxynucleotides. Invest Ophthalmol Vis Sci. 2012; 53:1130–8. [PubMed: 22247467]
- Guo CX, Tran H, Green CR, Danesh-Meyer HV, Acosta ML. Gap junction proteins in the lightdamaged albino rat. Mol Vis. 2014; 20:670–82. [PubMed: 24883012]
- Gupta A, Niger C, Buo AM, Eidelman ER, Chen RJ, Stains JP. Connexin43 enhances the expression of osteoarthritis-associated genes in synovial fibroblasts in culture. BMC Musculoskelet Disord. 2014; 15:425. [PubMed: 25496568]
- Haass NK, Smalley KS, Herlyn M. The role of altered cell-cell communication in melanoma progression. J Mol Histol. 2004; 35:309–18. [PubMed: 15339050]
- Haghikia A, Ladage K, Hinkerohe D, Vollmar P, Heupel K, Dermietzel R, Faustmann PM. Implications of antiinflammatory properties of the anticonvulsant drug levetiracetam in astrocytes. J Neurosci Res. 2008a; 86:1781–8. [PubMed: 18335543]
- Haghikia A, Ladage K, Lafênetre P, Hinkerohe D, Smikalla D, Haase CG, Dermietzel R, Faustmann PM. Intracellular application of TNF-alpha impairs cell to cell communication via gap junctions in glioma cells. J Neurooncol. 2008b; 86:143–52. [PubMed: 17690839]
- Hakim CH, Jackson WF, Segal SS. Connexin isoform expression in smooth muscle cells and endothelial cells of hamster cheek pouch arterioles and retractor feed arteries. Microcirculation. 2008; 15:503–14. [PubMed: 19086260]
- Hanner F, Sorensen CM, Holstein-Rathlou NH, Peti-Peterdi J. Connexins and the kidney. Am J Physiol Regul Integr Comp Physiol. 2010; 298:R1143–55. [PubMed: 20164205]
- Hernández-Guerra M, González-Méndez Y, De Ganzo ZA, Salido E, García-Pagán JC, Abrante B, Malagón AM, Bosch J, Quintero E. Role of gap junctions modulating hepatic vascular tone in cirrhosis. Liver Int. 2014; 34:859–68. [PubMed: 24350605]
- Hillis GS, Duthie LA, Brown PA, Simpson JG, Macleod AM, Haites NE. Upregulation and colocalization of connexin43 and cellular adhesion molecules in inflammatory renal disease. J Pathol. 1997a; 182:373–9. [PubMed: 9306956]
- Hillis GS, Duthie LA, Mlynski R, Mckay NG, Mistry S, Macleod AM, Simpson JG, Haites NE. The expression of connexin 43 in human kidney and cultured renal cells. Nephron. 1997b; 75:458–63. [PubMed: 9127334]
- Hills CE, Bland R, Bennett J, Ronco PM, Squires PE. TGF-beta1 mediates glucose-evoked upregulation of connexin-43 cell-to-cell communication in HCD-cells. Cell Physiol Biochem. 2009; 24:177–86. [PubMed: 19710532]
- Hinkerohe D, Smikalla D, Schoebel A, Haghikia A, Zoidl G, Haase CG, Schlegel U, Faustmann PM. Dexamethasone prevents LPS-induced microglial activation and astroglial impairment in an experimental bacterial meningitis co-culture model. Brain Res. 2010; 1329:45–54. [PubMed: 20230803]
- Hou CJ, Tsai CH, Yeh HI. Endothelial connexins are down-regulated by atherogenic factors. Front Biosci. 2008; 13:3549–57. [PubMed: 18508454]
- Huang C, Han X, Li X, Lam E, Peng W, Lou N, Torres A, Yang M, Garre JM, Tian GF, Bennett MV, et al. Critical role of connexin 43 in secondary expansion of traumatic spinal cord injury. J Neurosci. 2012; 32:3333–8. [PubMed: 22399755]
- Huang S, Dudez T, Scerri I, Thomas MA, Giepmans BN, Suter S, Chanson M. Defective activation of c-Src in cystic fibrosis airway epithelial cells results in loss of tumor necrosis factor-alphainduced gap junction regulation. J Biol Chem. 2003a; 278:8326–32. [PubMed: 12506110]

- Huang S, Jornot L, Wiszniewski L, Rochat T, Suter S, Lacroix JS, Chanson M. Src signaling links mediators of inflammation to Cx43 gap junction channels in primary and transformed CFTR-expressing airway cells. Cell Commun Adhes. 2003b; 10:279–85. [PubMed: 14681029]
- Husøy T, Ølstørn HB, Knutsen HK, Løberg EM, Cruciani V, Mikalsen SO, Goverud IL, Alexander J. Truncated mouse adenomatous polyposis coli reduces connexin32 content and increases matrilysin secretion from Paneth cells. Eur J Cancer. 2004; 40:1599–603. [PubMed: 15196546]
- Igarashi I, Maejima T, Kai K, Arakawa S, Teranishi M, Sanbuissho A. Role of connexin 32 in acetaminophen toxicity in a knockout mice model. Exp Toxicol Pathol. 2014; 66:103–10. [PubMed: 24263089]
- Ismail R, Rashid R, Andrabi K, Parray FQ, Besina S, Shah MA, Ul Hussain M. Pathological implications of Cx43 down-regulation in human colon cancer. Asian Pac J Cancer Prev. 2014; 15:2987–91. [PubMed: 24815435]
- Ito T, Ogoshi K, Nakano I, Ueda F, Sakai H, Kinjo M, Nawata H. Effect of Irsogladine on gap junctions in cerulein-induced acute pancreatitis in rats. Pancreas. 1997; 15:297–303. [PubMed: 9336795]
- Iwata F, Joh T, Ueda F, Yokoyama Y, Itoh M. Role of gap junctions in inhibiting ischemia-reperfusion injury of rat gastric mucosa. Am J Physiol. 1998; 275:G883–8. [PubMed: 9815015]
- Iyyathurai J, D'hondt C, Wang N, De Bock M, Himpens B, Retamal MA, Stehberg J, Leybaert L, Bultynck G. Peptides and peptide-derived molecules targeting the intracellular domains of Cx43: gap junctions versus hemichannels. Neuropharmacology. 2013; 75:491–505. [PubMed: 23664811]
- Jansen JA, Van Veen TA, De Bakker JM, Van Rijen HV. Cardiac connexins and impulse propagation. J Mol Cell Cardiol. 2010; 48:76–82. [PubMed: 19729017]
- Jia Y, Xu CX, Yang WB. [Expressions of connexin 32 and connexin 43 in patients with gastric precancerous lesion after eradication of Helicobacter pylori]. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2008; 33:628–33. [PubMed: 18667778]
- John GR, Scemes E, Suadicani SO, Liu JS, Charles PC, Lee SC, Spray DC, Brosnan CF. IL-1beta differentially regulates calcium wave propagation between primary human fetal astrocytes via pathways involving P2 receptors and gap junction channels. Proc Natl Acad Sci U S A. 1999; 96:11613–8. [PubMed: 10500225]
- Johnstone S, Isakson B, Locke D. Biological and biophysical properties of vascular connexin channels. Int Rev Cell Mol Biol. 2009; 278:69–118. [PubMed: 19815177]
- Johnstone SR, Billaud M, Lohman AW, Taddeo EP, Isakson BE. Posttranslational modifications in connexins and pannexins. J Membr Biol. 2012; 245:319–32. [PubMed: 22739962]
- Kanady JD, Dellinger MT, Munger SJ, Witte MH, Simon AM. Connexin37 and Connexin43 deficiencies in mice disrupt lymphatic valve development and result in lymphatic disorders including lymphedema and chylothorax. Dev Biol. 2011; 354:253–66. [PubMed: 21515254]
- Kanady JD, Munger SJ, Witte MH, Simon AM. Combining Foxc2 and Connexin37 deletions in mice leads to severe defects in lymphatic vascular growth and remodeling. Dev Biol. 2015; 405:33–46. [PubMed: 26079578]
- Kanczuga-Koda L, Sulkowski S, Koda M, Sobaniec-Lotowska M, Sulkowska M. Expression of connexins 26, 32 and 43 in the human colon--an immunohistochemical study. Folia Histochem Cytobiol. 2004; 42:203–7. [PubMed: 15704645]
- Kandasamy K, Escue R, Manna J, Adebiyi A, Parthasarathi K. Changes in endothelial connexin 43 expression inversely correlate with microvessel permeability and VE-cadherin expression in endotoxin-challenged lungs. Am J Physiol Lung Cell Mol Physiol. 2015; 309:L584–92. [PubMed: 26163513]
- Karpuk N, Burkovetskaya M, Fritz T, Angle A, Kielian T. Neuroinflammation leads to regiondependent alterations in astrocyte gap junction communication and hemichannel activity. J Neurosci. 2011; 31:414–25. [PubMed: 21228152]
- Kato R, Ishihara Y, Kawanabe N, Sumiyoshi K, Yoshikawa Y, Nakamura M, Imai Y, Yanagita T, Fukushima H, Kamioka H, Takano-Yamamoto T, et al. Gap-junction-mediated communication in human periodontal ligament cells. J Dent Res. 2013; 92:635–40. [PubMed: 23677649]

- Kawai T, Akira S. Signaling to NF-kappaB by Toll-like receptors. Trends Mol Med. 2007; 13:460–9. [PubMed: 18029230]
- Kielian T. Glial connexins and gap junctions in CNS inflammation and disease. J Neurochem. 2008; 106:1000–16. [PubMed: 18410504]
- Kim Y, Davidson JO, Gunn KC, Phillips AR, Green CR, Gunn AJ. Role of Hemichannels in CNS Inflammation and the Inflammasome Pathway. Adv Protein Chem Struct Biol. 2016; 104:1–37. [PubMed: 27038371]
- Kimura K, Orita T, Morishige N, Nishida T, Sonoda KH. Role of the JNK signaling pathway in downregulation of connexin43 by TNF-a in human corneal fibroblasts. Curr Eye Res. 2013; 38:926–32. [PubMed: 23768164]
- Koval M. Sharing signals: connecting lung epithelial cells with gap junction channels. Am J Physiol Lung Cell Mol Physiol. 2002; 283:L875–93. [PubMed: 12376339]
- Krüger O, Plum A, Kim JS, Winterhager E, Maxeiner S, Hallas G, Kirchhoff S, Traub O, Lamers WH, Willecke K. Defective vascular development in connexin 45-deficient mice. Development. 2000; 127:4179–93. [PubMed: 10976050]
- Kunzelmann P, Blümcke I, Traub O, Dermietzel R, Willecke K. Coexpression of connexin45 and -32 in oligodendrocytes of rat brain. J Neurocytol. 1997; 26:17–22. [PubMed: 9154525]
- Kurtz L, Schweda F, De Wit C, Kriz W, Witzgall R, Warth R, Sauter A, Kurtz A, Wagner C. Lack of connexin 40 causes displacement of renin-producing cells from afferent arterioles to the extraglomerular mesangium. J Am Soc Nephrol. 2007; 18:1103–11. [PubMed: 17329574]
- Kwak BR, Bäck M, Bochaton-Piallat ML, Caligiuri G, Daemen MJ, Davies PF, Hoefer IE, Holvoet P, Jo H, Krams R, Lehoux S, et al. Biomechanical factors in atherosclerosis: mechanisms and clinical implications. Eur Heart J. 2014; 35:3013–20. 3020a-3020d. [PubMed: 25230814]
- Kwak BR, Mulhaupt F, Veillard N, Gros DB, Mach F. Altered pattern of vascular connexin expression in atherosclerotic plaques. Arterioscler Thromb Vasc Biol. 2002; 22:225–30. [PubMed: 11834520]
- Kwak BR, Veillard N, Pelli G, Mulhaupt F, James RW, Chanson M, Mach F. Reduced connexin43 expression inhibits atherosclerotic lesion formation in low-density lipoprotein receptor-deficient mice. Circulation. 2003; 107:1033–9. [PubMed: 12600918]
- Kyoi T, Ueda F, Kimura K, Yamamoto M, Kataoka K. Development of gap junctions between gastric surface mucous cells during cell maturation in rats. Gastroenterology. 1992; 102:1930–5. [PubMed: 1587411]
- Laird DW. Connexin phosphorylation as a regulatory event linked to gap junction internalization and degradation. Biochim Biophys Acta. 2005; 1711:172–82. [PubMed: 15955302]
- Laird DW. Life cycle of connexins in health and disease. Biochem J. 2006; 394:527–43. [PubMed: 16492141]
- Lampe PD, Lau AF. The effects of connexin phosphorylation on gap junctional communication. Int J Biochem Cell Biol. 2004; 36:1171–86. [PubMed: 15109565]
- Leaphart CL, Qureshi F, Cetin S, Li J, Dubowski T, Baty C, Batey C, Beer-Stolz D, Guo F, Murray SA, Hackam DJ. Interferon-gamma inhibits intestinal restitution by preventing gap junction communication between enterocytes. Gastroenterology. 2007; 132:2395–411. [PubMed: 17570214]
- Ledeen RW, Chakraborty G. Cytokines, signal transduction, and inflammatory demyelination: review and hypothesis. Neurochem Res. 1998; 23:277–89. [PubMed: 9482240]
- Lee IH, Lindqvist E, Kiehn O, Widenfalk J, Olson L. Glial and neuronal connexin expression patterns in the rat spinal cord during development and following injury. J Comp Neurol. 2005; 489:1–10. [PubMed: 15977163]
- Levit NA, White TW. Connexin hemichannels influence genetically determined inflammatory and hyperproliferative skin diseases. Pharmacol Res. 2015; 99:337–43. [PubMed: 26211951]
- Li L, Zhang W, Shi WY, Ma KT, Zhao L, Wang Y, Zhang L, Li XZ, Zhu H, Zhang ZS, Liu WD, et al. The enhancement of Cx45 expression and function in renal interlobar artery of spontaneously hypertensive rats at different age. Kidney Blood Press Res. 2015a; 40:52–65. [PubMed: 25791497]

- Li X, Zhou Z, Dou K, Wang Y. Connexin evolution ameliorates the risk of various cancers. Eur Rev Med Pharmacol Sci. 2015b; 19:1662–72. [PubMed: 26004607]
- Liao CK, Wang SM, Chen YL, Wang HS, Wu JC. Lipopolysaccharide-induced inhibition of connexin43 gap junction communication in astrocytes is mediated by downregulation of caveolin-3. Int J Biochem Cell Biol. 2010; 42:762–70. [PubMed: 20093193]
- Lieury A, Chanal M, Androdias G, Reynolds R, Cavagna S, Giraudon P, Confavreux C, Nataf S. Tissue remodeling in periplaque regions of multiple sclerosis spinal cord lesions. Glia. 2014; 62:1645–58. [PubMed: 24910450]
- Little TL, Beyer EC, Duling BR. Connexin 43 and connexin 40 gap junctional proteins are present in arteriolar smooth muscle and endothelium in vivo. Am J Physiol. 1995; 268:H729–39. [PubMed: 7864199]
- Liu X, Furuya T, Li D, Xu J, Cao X, Li Q, Xu Z, Sasaki K. Connexin 26 expression correlates with less aggressive phenotype of intestinal type-gastric carcinomas. Int J Mol Med. 2010; 25:709–16. [PubMed: 20372813]
- Liu XH, Zhang JP, He SY, Song WF. [Expression of Cx43 and Pax3 in the small intestinal muscular layers of early human embryos]. Nan Fang Yi Ke Da Xue Xue Bao. 2008; 28:634–6. [PubMed: 18495608]
- Losa D, Chanson M. The lung communication network. Cell Mol Life Sci. 2015; 72:2793–808. [PubMed: 26100513]
- Losso JN, Truax RE, Richard G. trans-resveratrol inhibits hyperglycemia-induced inflammation and connexin downregulation in retinal pigment epithelial cells. J Agric Food Chem. 2010; 58:8246–52. [PubMed: 20578705]
- Lu YC, Yeh WC, Ohashi PS. LPS/TLR4 signal transduction pathway. Cytokine. 2008; 42:145–51. [PubMed: 18304834]
- Lucas K, Maes M. Role of the Toll Like receptor (TLR) radical cycle in chronic inflammation: possible treatments targeting the TLR4 pathway. Mol Neurobiol. 2013; 48:190–204. [PubMed: 23436141]
- Luckprom P, Kanjanamekanant K, Pavasant P. Role of connexin43 hemichannels in mechanical stressinduced ATP release in human periodontal ligament cells. J Periodontal Res. 2011; 46:607–15. [PubMed: 21615411]
- Lutz SE, Raine CS, Brosnan CF. Loss of astrocyte connexins 43 and 30 does not significantly alter susceptibility or severity of acute experimental autoimmune encephalomyelitis in mice. J Neuroimmunol. 2012; 245:8–14. [PubMed: 22342190]
- Maccallum NS, Evans TW. Epidemiology of acute lung injury. Curr Opin Crit Care. 2005; 11:43–9. [PubMed: 15659944]
- Maes M, Cogliati B, Crespo Yanguas S, Willebrords J, Vinken M. Roles of connexins and pannexins in digestive homeostasis. Cell Mol Life Sci. 2015a; 72:2809–21. [PubMed: 26084872]
- Maes M, Crespo Yanguas S, Willebrords J, Cogliati B, Vinken M. Connexin and pannexin signaling in gastrointestinal and liver disease. Transl Res. 2015b; 166:332–43. [PubMed: 26051630]
- Maes M, Decrock E, Cogliati B, Oliveira AG, Marques PE, Dagli ML, Menezes GB, Mennecier G, Leybaert L, Vanhaecke T, Rogiers V, et al. Connexin and pannexin (hemi)channels in the liver. Front Physiol. 2014; 4:405. [PubMed: 24454290]
- Maes M, Mcgill MR, Da Silva TC, Abels C, Lebofsky M, De Araújo CM, Tiburcio T, Pereira IV, Willebrords J, Crespo Yanguas S, et al. Involvement of connexin43 in acetaminophen-induced liver injury. Biochim Biophys Acta. 2016a
- Maes M, Mcgill MR, Da Silva TC, Lebofsky M, Maria Monteiro De Araújo C, Tiburcio T, Veloso Alves Pereira I, Willebrords J, Crespo Yanguas S, Farhood A, et al. Connexin32: a mediator of acetaminophen-induced liver injury? Toxicol Mech Methods. 2016b:1–9. [PubMed: 26275125]
- Man YK, Trolove C, Tattersall D, Thomas AC, Papakonstantinopoulou A, Patel D, Scott C, Chong J, Jagger DJ, O'toole EA, Navsaria H, et al. A deafness-associated mutant human connexin 26 improves the epithelial barrier in vitro. J Membr Biol. 2007; 218:29–37. [PubMed: 17581693]
- Markoullis K, Sargiannidou I, Gardner C, Hadjisavvas A, Reynolds R, Kleopa KA. Disruption of oligodendrocyte gap junctions in experimental autoimmune encephalomyelitis. Glia. 2012a; 60:1053–66. [PubMed: 22461072]

- Markoullis K, Sargiannidou I, Schiza N, Hadjisavvas A, Roncaroli F, Reynolds R, Kleopa KA. Gap junction pathology in multiple sclerosis lesions and normal-appearing white matter. Acta Neuropathol. 2012b; 123:873–86. [PubMed: 22484441]
- Markoullis K, Sargiannidou I, Schiza N, Roncaroli F, Reynolds R, Kleopa KA. Oligodendrocyte gap junction loss and disconnection from reactive astrocytes in multiple sclerosis gray matter. J Neuropathol Exp Neurol. 2014; 73:865–79. [PubMed: 25101702]
- Martin PE. Connexins help fill the Gap: markers and therapeutic targets for chronic nonhealing wounds. Br J Dermatol. 2015; 173:1123–4. [PubMed: 26769640]
- Martin PE, Easton JA, Hodgins MB, Wright CS. Connexins: sensors of epidermal integrity that are therapeutic targets. FEBS Lett. 2014; 588:1304–14. [PubMed: 24607543]
- Martin PE, Van Steensel M. Connexins and skin disease: insights into the role of beta connexins in skin homeostasis. Cell Tissue Res. 2015; 360:645–58. [PubMed: 25616557]
- Matsue H, Yao J, Matsue K, Nagasaka A, Sugiyama H, Aoki R, Kitamura M, Shimada S. Gap junction-mediated intercellular communication between dendritic cells (DCs) is required for effective activation of DCs. J Immunol. 2006; 176:181–90. [PubMed: 16365409]
- Mattii L, Ippolito C, Segnani C, Battolla B, Colucci R, Dolfi A, Bassotti G, Blandizzi C, Bernardini N. Altered expression pattern of molecular factors involved in colonic smooth muscle functions: an immunohistochemical study in patients with diverticular disease. PLoS One. 2013; 8:e57023. [PubMed: 23437299]
- Mayan MD, Carpintero-Fernandez P, Gago-Fuentes R, Martinez-De-Ilarduya O, Wang HZ, Valiunas V, Brink P, Blanco FJ. Human articular chondrocytes express multiple gap junction proteins: differential expression of connexins in normal and osteoarthritic cartilage. Am J Pathol. 2013; 182:1337–46. [PubMed: 23416160]
- Mcclain JL, Grubiši V, Fried D, Gomez-Suarez RA, Leinninger GM, Sévigny J, Parpura V, Gulbransen BD. Ca2+ responses in enteric glia are mediated by connexin-43 hemichannels and modulate colonic transit in mice. Gastroenterology. 2014; 146:497–507.e1. [PubMed: 24211490]
- Meens MJ, Kwak BR, Duffy HS. Role of connexins and pannexins in cardiovascular physiology. Cell Mol Life Sci. 2015; 72:2779–92. [PubMed: 26091747]
- Meens MJ, Sabine A, Petrova TV, Kwak BR. Connexins in lymphatic vessel physiology and disease. FEBS Lett. 2014; 588:1271–7. [PubMed: 24457200]
- Mele T, Madrenas J. TLR2 signalling: At the crossroads of commensalism, invasive infections and toxic shock syndrome by Staphylococcus aureus. Int J Biochem Cell Biol. 2010; 42:1066–71. [PubMed: 20363358]
- Merrifield PA, Laird DW. Connexins in skeletal muscle development and disease. Semin Cell Dev Biol. 2015
- Meyer W, Oberthuer A, Ngezahayo A, Neumann U, Jacob R. Immunohistochemical demonstration of connexins in the developing feather follicle of the chicken. Acta Histochem. 2014; 116:639–45. [PubMed: 24345685]
- Michela P, Velia V, Aldo P, Ada P. Role of connexin 43 in cardiovascular diseases. Eur J Pharmacol. 2015; 768:71–6. [PubMed: 26499977]
- Miwa H, Endo K, Wada R, Hirai S, Hirose M, Misawa H, Nagahara A, Ohta K, Watanabe S, Sato N. Cellular proliferation and differentiation in rat atrophic gastric mucosa induced by N'-methyl-N'nitro-N-nitrosoguanidine. J Clin Gastroenterol. 1997; 25(Suppl 1):S116–21. [PubMed: 9479637]
- Moore K, Bryant ZJ, Ghatnekar G, Singh UP, Gourdie RG, Potts JD. A synthetic connexin 43 mimetic peptide augments corneal wound healing. Exp Eye Res. 2013; 115:178–88. [PubMed: 23876491]
- Moore KB, O'brien J. Connexins in neurons and glia: targets for intervention in disease and injury. Neural Regen Res. 2015; 10:1013–7. [PubMed: 26330808]
- Morel S, Burnier L, Kwak BR. Connexins participate in the initiation and progression of atherosclerosis. Semin Immunopathol. 2009; 31:49–61. [PubMed: 19404645]
- Mori R, Power KT, Wang CM, Martin P, Becker DL. Acute downregulation of connexin43 at wound sites leads to a reduced inflammatory response, enhanced keratinocyte proliferation and wound fibroblast migration. J Cell Sci. 2006; 119:5193–203. [PubMed: 17158921]

- Morioka T, Okada S, Nameta M, Kamal F, Yanakieva-Georgieva NT, Yao J, Sato A, Piao H, Oite T. Glomerular expression of connexin 40 and connexin 43 in rat experimental glomerulonephritis. Clin Exp Nephrol. 2013; 17:191–204. [PubMed: 22945766]
- Même W, Calvo CF, Froger N, Ezan P, Amigou E, Koulakoff A, Giaume C. Proinflammatory cytokines released from microglia inhibit gap junctions in astrocytes: potentiation by betaamyloid. FASEB J. 2006; 20:494–6. [PubMed: 16423877]
- Nagahara A, Watanabe S, Miwa H, Endo K, Hirose M, Sato N. Reduction of gap junction protein connexin 32 in rat atrophic gastric mucosa as an early event in carcinogenesis. J Gastroenterol. 1996; 31:491–7. [PubMed: 8844468]
- Nagasawa K, Chiba H, Fujita H, Kojima T, Saito T, Endo T, Sawada N. Possible involvement of gap junctions in the barrier function of tight junctions of brain and lung endothelial cells. J Cell Physiol. 2006; 208:123–32. [PubMed: 16547974]
- Nagy JI, Rash JE. Connexins and gap junctions of astrocytes and oligodendrocytes in the CNS. Brain Res Brain Res Rev. 2000; 32:29–44. [PubMed: 10751655]
- Naiki-Ito A, Asamoto M, Naiki T, Ogawa K, Takahashi S, Sato S, Shirai T. Gap junction dysfunction reduces acetaminophen hepatotoxicity with impact on apoptotic signaling and connexin 43 protein induction in rat. Toxicol Pathol. 2010; 38:280–6. [PubMed: 20097795]
- Nakashima Y, Ono T, Yamanoi A, El-Assal ON, Kohno H, Nagasue N. Expression of gap junction protein connexin32 in chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma. J Gastroenterol. 2004; 39:763–8. [PubMed: 15338370]
- Navab M, Liao F, Hough GP, Ross LA, Van Lenten BJ, Rajavashisth TB, Lusis AJ, Laks H, Drinkwater DC, Fogelman AM. Interaction of monocytes with cocultures of human aortic wall cells involves interleukins 1 and 6 with marked increases in connexin43 message. J Clin Invest. 1991; 87:1763–72. [PubMed: 1850762]
- Neijssen J, Pang B, Neefjes J. Gap junction-mediated intercellular communication in the immune system. Prog Biophys Mol Biol. 2007; 94:207–18. [PubMed: 17467043]
- Nemeth L, Maddur S, Puri P. Immunolocalization of the gap junction protein Connexin43 in the interstitial cells of Cajal in the normal and Hirschsprung's disease bowel. J Pediatr Surg. 2000; 35:823–8. [PubMed: 10873019]
- Neub A, Houdek P, Ohnemus U, Moll I, Brandner JM. Biphasic regulation of AP-1 subunits during human epidermal wound healing. J Invest Dermatol. 2007; 127:2453–62. [PubMed: 17495958]
- Nishitani A, Hirota S, Nishida T, Isozaki K, Hashimoto K, Nakagomi N, Matsuda H. Differential expression of connexin 43 in gastrointestinal stromal tumours of gastric and small intestinal origin. J Pathol. 2005; 206:377–82. [PubMed: 15938003]
- Norenberg MD, Smith J, Marcillo A. The pathology of human spinal cord injury: defining the problems. J Neurotrauma. 2004; 21:429–40. [PubMed: 15115592]
- O'carroll SJ, Alkadhi M, Nicholson LF, Green CR. Connexin 43 mimetic peptides reduce swelling, astrogliosis, and neuronal cell death after spinal cord injury. Cell Commun Adhes. 2008; 15:27– 42. [PubMed: 18649176]
- O'carroll SJ, Gorrie CA, Velamoor S, Green CR, Nicholson LF. Connexin43 mimetic peptide is neuroprotective and improves function following spinal cord injury. Neurosci Res. 2013; 75:256– 67. [PubMed: 23403365]
- O'donnell JJ, Birukova AA, Beyer EC, Birukov KG. Gap junction protein connexin43 exacerbates lung vascular permeability. PLoS One. 2014; 9:e100931. [PubMed: 24967639]
- Odermatt B, Wellershaus K, Wallraff A, Seifert G, Degen J, Euwens C, Fuss B, Büssow H, Schilling K, Steinhäuser C, Willecke K. Connexin 47 (Cx47)-deficient mice with enhanced green fluorescent protein reporter gene reveal predominant oligodendrocytic expression of Cx47 and display vacuolized myelin in the CNS. J Neurosci. 2003; 23:4549–59. [PubMed: 12805295]
- Ogoshi K, Ito T, Igarashi H, Arita Y, Hisano T, Sumii T, Nawata H. The time course of gap-junctional protein connexin 32 expression in the pancreas after the induction of acute pancreatitis by caerulein in rats. J Gastroenterol. 2002; 37:633–9. [PubMed: 12203079]
- Ohkusa T, Fujiki K, Tamura Y, Yamamoto M, Kyoi T. Freeze-fracture and immunohistochemical studies of gap junctions in human gastric mucosa with special reference to their relationship to gastric ulcer and gastric carcinoma. Microsc Res Tech. 1995; 31:226–33. [PubMed: 7670161]

- Oishi S, Sasano T, Tateishi Y, Tamura N, Isobe M, Furukawa T. Stretch of atrial myocytes stimulates recruitment of macrophages via ATP released through gap-junction channels. J Pharmacol Sci. 2012; 120:296–304. [PubMed: 23196902]
- Ongstad EL, O'quinn MP, Ghatnekar GS, Yost MJ, Gourdie RG. A Connexin43 Mimetic Peptide Promotes Regenerative Healing and Improves Mechanical Properties in Skin and Heart. Adv Wound Care (New Rochelle). 2013; 2:55–62. [PubMed: 24527326]
- Orellana JA, Hernández DE, Ezan P, Velarde V, Bennett MV, Giaume C, Sáez JC. Hypoxia in high glucose followed by reoxygenation in normal glucose reduces the viability of cortical astrocytes through increased permeability of connexin 43 hemichannels. Glia. 2010; 58:329–43. [PubMed: 19705457]
- Orellana JA, Shoji KF, Abudara V, Ezan P, Amigou E, Sáez PJ, Jiang JX, Naus CC, Sáez JC, Giaume C. Amyloid β-induced death in neurons involves glial and neuronal hemichannels. J Neurosci. 2011; 31:4962–77. [PubMed: 21451035]
- Orellana JA, Sáez JC, Bennett MV, Berman JW, Morgello S, Eugenin EA. HIV increases the release of dickkopf-1 protein from human astrocytes by a Cx43 hemichannel-dependent mechanism. J Neurochem. 2014; 128:752–63. [PubMed: 24134157]
- Orellana JA, Sáez PJ, Shoji KF, Schalper KA, Palacios-Prado N, Velarde V, Giaume C, Bennett MV, Sáez JC. Modulation of brain hemichannels and gap junction channels by pro-inflammatory agents and their possible role in neurodegeneration. Antioxid Redox Signal. 2009; 11:369–99. [PubMed: 18816186]
- Ormonde S, Chou CY, Goold L, Petsoglou C, Al-Taie R, Sherwin T, Mcghee CN, Green CR. Regulation of connexin43 gap junction protein triggers vascular recovery and healing in human ocular persistent epithelial defect wounds. J Membr Biol. 2012; 245:381–8. [PubMed: 22797940]
- Oviedo-Orta E, Gasque P, Evans WH. Immunoglobulin and cytokine expression in mixed lymphocyte cultures is reduced by disruption of gap junction intercellular communication. FASEB J. 2001; 15:768–74. [PubMed: 11259395]
- Oviedo-Orta E, Howard Evans W. Gap junctions and connexin-mediated communication in the immune system. Biochim Biophys Acta. 2004; 1662:102–12. [PubMed: 15033582]
- Oviedo-Orta E, Hoy T, Evans WH. Intercellular communication in the immune system: differential expression of connexin40 and 43, and perturbation of gap junction channel functions in peripheral blood and tonsil human lymphocyte subpopulations. Immunology. 2000; 99:578–90. [PubMed: 10792506]
- Pacheco-Costa R, Hassan I, Reginato RD, Davis HM, Bruzzaniti A, Allen MR, Plotkin LI. High bone mass in mice lacking Cx37 because of defective osteoclast differentiation. J Biol Chem. 2014; 289:8508–20. [PubMed: 24509854]
- Paic F, Igwe JC, Nori R, Kronenberg MS, Franceschetti T, Harrington P, Kuo L, Shin DG, Rowe DW, Harris SE, Kalajzic I. Identification of differentially expressed genes between osteoblasts and osteocytes. Bone. 2009; 45:682–92. [PubMed: 19539797]
- Parenti R, Campisi A, Vanella A, Cicirata F. Immunocytochemical and RT-PCR analysis of connexin36 in cultures of mammalian glial cells. Arch Ital Biol. 2002; 140:101–8. [PubMed: 12004642]
- Park SJ, Lee KS, Kim SR, Min KH, Lee KY, Choe YH, Park SY, Hong SH, Lee YC. Change of connexin 37 in allergen-induced airway inflammation. Exp Mol Med. 2007; 39:629–40. [PubMed: 18059139]
- Parthasarathi K, Ichimura H, Monma E, Lindert J, Quadri S, Issekutz A, Bhattacharya J. Connexin 43 mediates spread of Ca2+-dependent proinflammatory responses in lung capillaries. J Clin Invest. 2006; 116:2193–200. [PubMed: 16878174]
- Penuela S, Gyenis L, Ablack A, Churko JM, Berger AC, Litchfield DW, Lewis JD, Laird DW. Loss of pannexin 1 attenuates melanoma progression by reversion to a melanocytic phenotype. J Biol Chem. 2012; 287:29184–93. [PubMed: 22753409]
- Pfenniger A, Chanson M, Kwak BR. Connexins in atherosclerosis. Biochim Biophys Acta. 2013; 1828:157–66. [PubMed: 22609170]


- Pfenniger A, Meens MJ, Pedrigi RM, Foglia B, Sutter E, Pelli G, Rochemont V, Petrova TV, Krams R, Kwak BR. Shear stress-induced atherosclerotic plaque composition in ApoE(-/-) mice is modulated by connexin37. Atherosclerosis. 2015; 243:1–10. [PubMed: 26342936]
- Plotkin LI, Bellido T. Beyond gap junctions: Connexin43 and bone cell signaling. Bone. 2013; 52:157–66. [PubMed: 23041511]
- Plotkin LI, Manolagas SC, Bellido T. Transduction of cell survival signals by connexin-43 hemichannels. J Biol Chem. 2002; 277:8648–57. [PubMed: 11741942]
- Polacek D, Bech F, Mckinsey JF, Davies PF. Connexin43 gene expression in the rabbit arterial wall: effects of hypercholesterolemia, balloon injury and their combination. J Vasc Res. 1997; 34:19– 30. [PubMed: 9075822]
- Pollok S, Pfeiffer AC, Lobmann R, Wright CS, Moll I, Martin PE, Brandner JM. Connexin 43 mimetic peptide Gap27 reveals potential differences in the role of Cx43 in wound repair between diabetic and non-diabetic cells. J Cell Mol Med. 2011; 15:861–73. [PubMed: 20345849]
- Qiu C, Coutinho P, Frank S, Franke S, Law LY, Martin P, Green CR, Becker DL. Targeting connexin43 expression accelerates the rate of wound repair. Curr Biol. 2003; 13:1697–703. [PubMed: 14521835]
- Quintanilla RA, Orellana JA, Von Bernhardi R. Understanding risk factors for Alzheimer's disease: interplay of neuroinflammation, connexin-based communication and oxidative stress. Arch Med Res. 2012; 43:632–44. [PubMed: 23142264]
- Radebold K, Horakova E, Gloeckner J, Ortega G, Spray DC, Vieweger H, Siebert K, Manuelidis L, Geibel JP. Gap junctional channels regulate acid secretion in the mammalian gastric gland. J Membr Biol. 2001; 183:147–53. [PubMed: 11696856]
- Retamal MA, Froger N, Palacios-Prado N, Ezan P, Sáez PJ, Sáez JC, Giaume C. Cx43 hemichannels and gap junction channels in astrocytes are regulated oppositely by proinflammatory cytokines released from activated microglia. J Neurosci. 2007; 27:13781–92. [PubMed: 18077690]
- Rezze GG, Fregnani JH, Duprat J, Landman G. Cell adhesion and communication proteins are differentially expressed in melanoma progression model. Hum Pathol. 2011; 42:409–18. [PubMed: 21193224]
- Rhett JM, Gourdie RG. The perinexus: a new feature of Cx43 gap junction organization. Heart Rhythm. 2012; 9:619–23. [PubMed: 21978964]
- Richard G. Connexins: a connection with the skin. Exp Dermatol. 2000; 9:77–96. [PubMed: 10772382]
- Rignault S, Haefliger JA, Waeber B, Liaudet L, Feihl F. Acute inflammation decreases the expression of connexin 40 in mouse lung. Shock. 2007; 28:78–85. [PubMed: 17483738]
- Riquelme MA, Jiang JX. Elevated Intracellular Ca(2+) Signals by Oxidative Stress Activate Connexin 43 Hemichannels in Osteocytes. Bone Res. 2013; 1:355–61. [PubMed: 26273513]
- Robertson J, Lang S, Lambert PA, Martin PE. Peptidoglycan derived from Staphylococcus epidermidis induces Connexin43 hemichannel activity with consequences on the innate immune response in endothelial cells. Biochem J. 2010; 432:133–43. [PubMed: 20815816]
- Sabine A, Agalarov Y, Maby-El Hajjami H, Jaquet M, Hägerling R, Pollmann C, Bebber D, Pfenniger A, Miura N, Dormond O, Calmes JM, et al. Mechanotransduction, PROX1, and FOXC2 cooperate to control connexin37 and calcineurin during lymphatic-valve formation. Dev Cell. 2012; 22:430–45. [PubMed: 22306086]
- Sagawa H, Naiki-Ito A, Kato H, Naiki T, Yamashita Y, Suzuki S, Sato S, Shiomi K, Kato A, Kuno T, Matsuo Y, et al. Connexin 32 and luteolin play protective roles in non-alcoholic steatohepatitis development and its related hepatocarcinogenesis in rats. Carcinogenesis. 2015
- Sarieddine MZ, Scheckenbach KE, Foglia B, Maass K, Garcia I, Kwak BR, Chanson M. Connexin43 modulates neutrophil recruitment to the lung. J Cell Mol Med. 2009; 13:4560–70. [PubMed: 19166484]
- Sayyah M, Kaviani B, Khoshkholgh-Sima B, Bagheri M, Olad M, Choopani S, Mahdian R. Effect of chronic intracerebroventricluar administration of lipopolysaccharide on connexin43 protein expression in rat hippocampus. Iran Biomed J. 2012; 16:25–32. [PubMed: 22562029]
- Scheckenbach KE, Crespin S, Kwak BR, Chanson M. Connexin channel-dependent signaling pathways in inflammation. J Vasc Res. 2011; 48:91–103. [PubMed: 20926890]

- Schmidt VJ, Wölfle SE, Boettcher M, De Wit C. Gap junctions synchronize vascular tone within the microcirculation. Pharmacol Rep. 2008; 60:68–74. [PubMed: 18276987]
- Scott CA, Tattersall D, O'toole EA, Kelsell DP. Connexins in epidermal homeostasis and skin disease. Biochim Biophys Acta. 2012; 1818:1952–61. [PubMed: 21933662]
- Scully M, Gang C, Condron C, Bouchier-Hayes D, Cunningham AJ. Protective role of cyclooxygenase (COX)-2 in experimental lung injury: evidence of a lipoxin A4-mediated effect. J Surg Res. 2012; 175:176–84. [PubMed: 21944479]
- Sedhom MA, Pichery M, Murdoch JR, Foligné B, Ortega N, Normand S, Mertz K, Sanmugalingam D, Brault L, Grandjean T, Lefrancais E, et al. Neutralisation of the interleukin-33/ST2 pathway ameliorates experimental colitis through enhancement of mucosal healing in mice. Gut. 2013; 62:1714–23. [PubMed: 23172891]
- Seki K, Komuro T. Distribution of interstitial cells of Cajal and gap junction protein, Cx 43 in the stomach of wild-type and W/Wv mutant mice. Anat Embryol (Berl). 2002; 206:57–65. [PubMed: 12478368]
- Severs NJ, Dupont E, Coppen SR, Halliday D, Inett E, Baylis D, Rothery S. Remodelling of gap junctions and connexin expression in heart disease. Biochim Biophys Acta. 2004; 1662:138–48. [PubMed: 15033584]
- Shalapour S, Karin M. Immunity, inflammation, and cancer: an eternal fight between good and evil. J Clin Invest. 2015; 125:3347–55. [PubMed: 26325032]
- Shiojiri N, Niwa T, Sugiyama Y, Koike T. Preferential expression of connexin37 and connexin40 in the endothelium of the portal veins during mouse liver development. Cell Tissue Res. 2006; 324:547–52. [PubMed: 16505993]
- Simon AM, Mcwhorter AR, Chen H, Jackson CL, Ouellette Y. Decreased intercellular communication and connexin expression in mouse aortic endothelium during lipopolysaccharide-induced inflammation. J Vasc Res. 2004; 41:323–33. [PubMed: 15249738]
- Simpson C, Kelsell DP, Marchès O. Connexin 26 facilitates gastrointestinal bacterial infection in vitro. Cell Tissue Res. 2013; 351:107–16. [PubMed: 23138568]
- Smoot DT. How does Helicobacter pylori cause mucosal damage? Direct mechanisms. Gastroenterology. 1997; 113:S31–4. discussion S50. [PubMed: 9394757]
- Srinivas M, Calderon DP, Kronengold J, Verselis VK. Regulation of connexin hemichannels by monovalent cations. J Gen Physiol. 2006; 127:67–75. [PubMed: 16380444]
- Su M, Borke JL, Donahue HJ, Li Z, Warshawsky NM, Russell CM, Lewis JE. Expression of connexin 43 in rat mandibular bone and periodontal ligament (PDL) cells during experimental tooth movement. J Dent Res. 1997; 76:1357–66. [PubMed: 9207768]
- Su V, Lau AF. Connexins: mechanisms regulating protein levels and intercellular communication. FEBS Lett. 2014; 588:1212–20. [PubMed: 24457202]
- Sutcliffe JE, Chin KY, Thrasivoulou C, Serena TE, O'neil S, Hu R, White AM, Madden L, Richards T, Phillips AR, Becker DL. Abnormal connexin expression in human chronic wounds. Br J Dermatol. 2015; 173:1205–15. [PubMed: 26264563]
- Takeuchi H, Jin S, Wang J, Zhang G, Kawanokuchi J, Kuno R, Sonobe Y, Mizuno T, Suzumura A. Tumor necrosis factor-alpha induces neurotoxicity via glutamate release from hemichannels of activated microglia in an autocrine manner. J Biol Chem. 2006; 281:21362–8. [PubMed: 16720574]
- Takeuchi H, Suzumura A. Gap junctions and hemichannels composed of connexins: potential therapeutic targets for neurodegenerative diseases. Front Cell Neurosci. 2014; 8:189. [PubMed: 25228858]
- Tao R, Hu MF, Lou JT, Lei YL. Effects of H pylori infection on gap-junctional intercellular communication and proliferation of gastric epithelial cells in vitro. World J Gastroenterol. 2007; 13:5497–500. [PubMed: 17907295]
- Tarzemany R, Jiang G, Larjava H, Häkkinen L. Expression and function of connexin 43 in human gingival wound healing and fibroblasts. PLoS One. 2015; 10:e0115524. [PubMed: 25584940]
- Temme A, Ott T, Haberberger T, Traub O, Willecke K. Acute-phase response and circadian expression of connexin26 are not altered in connexin32-deficient mouse liver. Cell Tissue Res. 2000; 300:111–7. [PubMed: 10805080]

- Temme A, Traub O, Willecke K. Downregulation of connexin32 protein and gap-junctional intercellular communication by cytokine-mediated acute-phase response in immortalized mouse hepatocytes. Cell Tissue Res. 1998; 294:345–50. [PubMed: 9799450]
- Thompson LF, Eltzschig HK, Ibla JC, Van De Wiele CJ, Resta R, Morote-Garcia JC, Colgan SP. Crucial role for ecto-5'-nucleotidase (CD73) in vascular leakage during hypoxia. J Exp Med. 2004; 200:1395–405. [PubMed: 15583013]
- Tien T, Muto T, Barrette K, Challyandra L, Roy S. Downregulation of Connexin 43 promotes vascular cell loss and excess permeability associated with the development of vascular lesions in the diabetic retina. Mol Vis. 2014; 20:732–41. [PubMed: 24940027]
- Tien T, Muto T, Zhang J, Sohn EH, Mullins RF, Roy S. Association of reduced Connexin 43 expression with retinal vascular lesions in human diabetic retinopathy. Exp Eye Res. 2015; 146:103–106. [PubMed: 26738943]
- Tonkin RS, Mao Y, O'carroll SJ, Nicholson LF, Green CR, Gorrie CA, Moalem-Taylor G. Gap junction proteins and their role in spinal cord injury. Front Mol Neurosci. 2014; 7:102. [PubMed: 25610368]
- Toskala E. Immunology. Int Forum Allergy Rhinol. 2014; 4(Suppl 2):S21-7. [PubMed: 25182350]
- Toubas J, Beck S, Pageaud AL, Huby AC, Mael-Ainin M, Dussaule JC, Chatziantoniou C, Chadjichristos CE. Alteration of connexin expression is an early signal for chronic kidney disease. Am J Physiol Renal Physiol. 2011; 301:F24–32. [PubMed: 21429966]
- Tran Van Nhieu G, Clair C, Bruzzone R, Mesnil M, Sansonetti P, Combettes L. Connexin-dependent inter-cellular communication increases invasion and dissemination of Shigella in epithelial cells. Nat Cell Biol. 2003; 5:720–6. [PubMed: 12844145]
- Traoré A, Baudrimont I, Dano S, Sanni A, Larondelle Y, Schneider YJ, Creppy EE. Epigenetic properties of the diarrhetic marine toxin okadaic acid: inhibition of the gap junctional intercellular communication in a human intestine epithelial cell line. Arch Toxicol. 2003; 77:657–62. [PubMed: 14504690]
- Traub O, Hertlein B, Kasper M, Eckert R, Krisciukaitis A, Hülser D, Willecke K. Characterization of the gap junction protein connexin37 in murine endothelium, respiratory epithelium, and after transfection in human HeLa cells. Eur J Cell Biol. 1998; 77:313–22. [PubMed: 9930656]
- Tsuchida S, Arai Y, Kishida T, Takahashi KA, Honjo K, Terauchi R, Inoue H, Oda R, Mazda O, Kubo T. Silencing the expression of connexin 43 decreases inflammation and joint destruction in experimental arthritis. J Orthop Res. 2013; 31:525–30. [PubMed: 23165424]
- Uchida Y, Matsuda K, Sasahara K, Kawabata H, Nishioka M. Immunohistochemistry of gap junctions in normal and diseased gastric mucosa of humans. Gastroenterology. 1995; 109:1492–6. [PubMed: 7557130]
- Van Rijen HV, Van Kempen MJ, Postma S, Jongsma HJ. Tumour necrosis factor alpha alters the expression of connexin43, connexin40, and connexin37 in human umbilical vein endothelial cells. Cytokine. 1998; 10:258–64. [PubMed: 9617570]
- Vaure C, Liu Y. A comparative review of toll-like receptor 4 expression and functionality in different animal species. Front Immunol. 2014; 5:316. [PubMed: 25071777]
- Vinken M, Decrock E, De Vuyst E, Ponsaerts R, D'hondt C, Bultynck G, Ceelen L, Vanhaecke T, Leybaert L, Rogiers V. Connexins: sensors and regulators of cell cycling. Biochim Biophys Acta. 2011; 1815:13–25. [PubMed: 20801193]
- Vinken M, Decrock E, Leybaert L, Bultynck G, Himpens B, Vanhaecke T, Rogiers V. Non-channel functions of connexins in cell growth and cell death. Biochim Biophys Acta. 2012; 1818:2002–8. [PubMed: 21718687]
- Vinken M, Vanhaecke T, Papeleu P, Snykers S, Henkens T, Rogiers V. Connexins and their channels in cell growth and cell death. Cell Signal. 2006; 18:592–600. [PubMed: 16183253]
- Volmer JB, Thompson LF, Blackburn MR. Ecto-5'-nucleotidase (CD73)-mediated adenosine production is tissue protective in a model of bleomycin-induced lung injury. J Immunol. 2006; 176:4449–58. [PubMed: 16547283]
- Von Maltzahn J, Euwens C, Willecke K, Söhl G. The novel mouse connexin39 gene is expressed in developing striated muscle fibers. J Cell Sci. 2004; 117:5381–92. [PubMed: 15466892]

- Von Maltzahn J, Wulf V, Matern G, Willecke K. Connexin39 deficient mice display accelerated myogenesis and regeneration of skeletal muscle. Exp Cell Res. 2011; 317:1169–78. [PubMed: 21272575]
- Vozzi C, Dupont E, Coppen SR, Yeh HI, Severs NJ. Chamber-related differences in connexin expression in the human heart. J Mol Cell Cardiol. 1999; 31:991–1003. [PubMed: 10336839]
- Waghabi MC, Coutinho-Silva R, Feige JJ, Higuchi MEL, Becker D, Burnstock G, Araújo-Jorge TC. Gap junction reduction in cardiomyocytes following transforming growth factor-beta treatment and Trypanosoma cruzi infection. Mem Inst Oswaldo Cruz. 2009; 104:1083–90. [PubMed: 20140368]
- Wagner C, De Wit C, Kurtz L, Grünberger C, Kurtz A, Schweda F. Connexin40 is essential for the pressure control of renin synthesis and secretion. Circ Res. 2007; 100:556–63. [PubMed: 17255527]
- Wagner C, Jobs A, Schweda F, Kurtz L, Kurt B, Lopez ML, Gomez RA, Van Veen TA, De Wit C, Kurtz A. Selective deletion of Connexin 40 in renin-producing cells impairs renal baroreceptor function and is associated with arterial hypertension. Kidney Int. 2010; 78:762–8. [PubMed: 20686449]
- Wagner C, Kurtz A. Distribution and functional relevance of connexins in renin-producing cells. Pflugers Arch. 2013; 465:71–7. [PubMed: 22744230]
- Waisman A, Liblau RS, Becher B. Innate and adaptive immune responses in the CNS. Lancet Neurol. 2015; 14:945–55. [PubMed: 26293566]
- Wang CM, Lincoln J, Cook JE, Becker DL. Abnormal connexin expression underlies delayed wound healing in diabetic skin. Diabetes. 2007; 56:2809–17. [PubMed: 17717278]
- Wang N, De Bock M, Decrock E, Bol M, Gadicherla A, Bultynck G, Leybaert L. Connexin targeting peptides as inhibitors of voltage- and intracellular Ca2+-triggered Cx43 hemichannel opening. Neuropharmacology. 2013a; 75:506–16. [PubMed: 24007825]
- Wang N, De Bock M, Decrock E, Bol M, Gadicherla A, Vinken M, Rogiers V, Bukauskas FF, Bultynck G, Leybaert L. Paracrine signaling through plasma membrane hemichannels. Biochim Biophys Acta. 2013b; 1828:35–50. [PubMed: 22796188]
- Wang N, De Vuyst E, Ponsaerts R, Boengler K, Palacios-Prado N, Wauman J, Lai CP, De Bock M, Decrock E, Bol M, Vinken M, et al. Selective inhibition of Cx43 hemichannels by Gap19 and its impact on myocardial ischemia/reperfusion injury. Basic Res Cardiol. 2013c; 108:309. [PubMed: 23184389]
- Wang Y, Huang LH, Xu CX, Xiao J, Zhou L, Cao D, Liu XM, Qi Y. Connexin 32 and 43 promoter methylation in Helicobacter pylori-associated gastric tumorigenesis. World J Gastroenterol. 2014; 20:11770–9. [PubMed: 25206281]
- Wang YF, Daniel EE. Gap junctions in gastrointestinal muscle contain multiple connexins. Am J Physiol Gastrointest Liver Physiol. 2001; 281:G533–43. [PubMed: 11447034]
- Willebrords J, Pereira IV, Maes M, Crespo Yanguas S, Colle I, Van Den Bossche B, Da Silva TC, De Oliveira CP, Andraus W, Alves VA, Cogliati B, et al. Strategies, models and biomarkers in experimental non-alcoholic fatty liver disease research. Prog Lipid Res. 2015; 59:106–25. [PubMed: 26073454]
- Wiszniewski L, Sanz J, Scerri I, Gasparotto E, Dudez T, Lacroix JS, Suter S, Gallati S, Chanson M. Functional expression of connexin30 and connexin31 in the polarized human airway epithelium. Differentiation. 2007; 75:382–92. [PubMed: 17428265]
- Wong CW, Burger F, Pelli G, Mach F, Kwak BR. Dual benefit of reduced Cx43 on atherosclerosis in LDL receptor-deficient mice. Cell Commun Adhes. 2003; 10:395–400. [PubMed: 14681047]
- Wong CW, Christen T, Roth I, Chadjichristos CE, Derouette JP, Foglia BF, Chanson M, Goodenough DA, Kwak BR. Connexin37 protects against atherosclerosis by regulating monocyte adhesion. Nat Med. 2006; 12:950–4. [PubMed: 16862155]
- Wong KW, Isberg RR. Emerging views on integrin signaling via Rac1 during invasin-promoted bacterial uptake. Curr Opin Microbiol. 2005; 8:4–9. [PubMed: 15694850]
- Wright CS, Van Steensel MA, Hodgins MB, Martin PE. Connexin mimetic peptides improve cell migration rates of human epidermal keratinocytes and dermal fibroblasts in vitro. Wound Repair Regen. 2009; 17:240–9. [PubMed: 19320893]


- Xu C, Chen Y, Chen X, Wang F. Effects of different types of Helicobacter pylori on the gap junction intercellular communication in GES-1 cells. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2011; 36:294–300. [PubMed: 21566279]
- Xu CX, Jia Y, Yang WB, Wang F, Shen SR. [Relationship between Helicobacter pylori infection and expression of connexin (Cx) 32 and Cx43 genes in gastric cancer and gastric precancerous lesions]. Zhonghua Yi Xue Za Zhi. 2008a; 88:1523–7. [PubMed: 18956631]
- Xu CX, Jia Y, Yang WB, Zou HF, Wang F, Shen SR. [Helicobacter pylori infection and changes of cell gap junction of gastric epithelial cells in patients with gastric cancer and precancerous lesion]. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2008b; 33:338–43. [PubMed: 18460779]
- Xu CX, Qi YM, Yang WB, Wang F, Zhou JD, Shen SR. [Effect of CagA(+) helicobacter pylori strain on the expression of connexin 43 and cell proliferation in BGC-823 cells]. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2007; 32:288–94. [PubMed: 17478938]
- Yamamoto T, Kojima T, Murata M, Takano K, Go M, Chiba H, Sawada N. IL-1beta regulates expression of Cx32, occludin, and claudin-2 of rat hepatocytes via distinct signal transduction pathways. Exp Cell Res. 2004; 299:427–41. [PubMed: 15350541]
- Yamaoka K, Nouchi T, Kohashi T, Marumo F, Sato C. Expression of gap junction protein connexin 32 in chronic liver diseases. Liver. 2000a; 20:104–7. [PubMed: 10847477]
- Yamaoka Y, Sawa Y, Ebata N, Ibuki N, Yoshida S. Cultured periodontal ligament fibroblasts express diverse connexins. Tissue Cell. 2002; 34:375–80. [PubMed: 12441089]
- Yamaoka Y, Sawa Y, Ebata N, Ibuki N, Yoshida S, Kawasaki T. Double expressions of connexin 43 and 32 in human periodontal ligament fibroblasts. Tissue Cell. 2000b; 32:328–35. [PubMed: 11145016]
- Yang M, Wang B, Li M, Jiang B. Connexin 43 is involved in aldosterone-induced podocyte injury. Cell Physiol Biochem. 2014; 34:1652–62. [PubMed: 25401388]
- Ye Y, Perez-Polo JR, Aguilar D, Birnbaum Y. The potential effects of anti-diabetic medications on myocardial ischemia-reperfusion injury. Basic Res Cardiol. 2011; 106:925–52. [PubMed: 21892746]
- Yeh HI, Lu CS, Wu YJ, Chen CC, Hong RC, Ko YS, Shiao MS, Severs NJ, Tsai CH. Reduced expression of endothelial connexin37 and connexin40 in hyperlipidemic mice: recovery of connexin37 after 7-day simvastatin treatment. Arterioscler Thromb Vasc Biol. 2003; 23:1391–7. [PubMed: 12829525]
- Yokoyama K, Higashi H, Ishikawa S, Fujii Y, Kondo S, Kato H, Azuma T, Wada A, Hirayama T, Aburatani H, Hatakeyama M. Functional antagonism between Helicobacter pylori CagA and vacuolating toxin VacA in control of the NFAT signaling pathway in gastric epithelial cells. Proc Natl Acad Sci U S A. 2005; 102:9661–6. [PubMed: 15980153]
- Zhang F, Yao SY, Whetsell WO, Sriram S. Astrogliopathy and oligodendrogliopathy are early events in CNS demyelination. Glia. 2013a; 61:1261–73. [PubMed: 23832594]
- Zhang FF, Morioka N, Kitamura T, Hisaoka-Nakashima K, Nakata Y. Proinflammatory cytokines downregulate connexin 43-gap junctions via the ubiquitin-proteasome system in rat spinal astrocytes. Biochem Biophys Res Commun. 2015; 464:1202–8. [PubMed: 26212436]
- Zhang FF, Morioka N, Nakashima-Hisaoka K, Nakata Y. Spinal astrocytes stimulated by tumor necrosis factor-α and/or interferon-γ attenuate connexin 43-gap junction via c-jun terminal kinase activity. J Neurosci Res. 2013b; 91:745–56. [PubMed: 23553806]
- Zhang Q, Cao C, Mangano M, Zhang Z, Silldorff EP, Lee-Kwon W, Payne K, Pallone TL. Descending vasa recta endothelium is an electrical syncytium. Am J Physiol Regul Integr Comp Physiol. 2006; 291:R1688–99. [PubMed: 16840652]
- Zhao Q, Shao L, Hu X, Wu G, Du J, Xia J, Qiu H. Lipoxin a4 preconditioning and postconditioning protect myocardial ischemia/reperfusion injury in rats. Mediators Inflamm. 2013; 2013:231351. [PubMed: 23956501]
- Zvalova D, Cordier J, Mesnil M, Junier MP, Chneiweiss H. p38/SAPK2 controls gap junction closure in astrocytes. Glia. 2004; 46:323–33. [PubMed: 15048855]



#### Figure 1. Structure of connexins and their channels.

GJs appear as plaques at the cell plasma membrane surface and are formed by the interaction of 2 HCs of adjacent cells. Each HC is composed of 6 Cx proteins, which are transmembrane proteins consisting of a cytoplasmic loop, 2 extracellular loops, a cytoplasmic *C*-terminal tail and a cytoplasmic *N*-terminal tail. (CL, cytoplasmic loop; EL, extracellular loop; TM, transmembrane domain).





### Figure 2. Role of connexin signaling in the initiation of inflammation.

PAMPs or DAMPs can interact with Toll-like receptors, which undergo dimerization upon activation. This triggers the migration of NF- $\kappa\beta$  to the nucleus, where it activates gene transcription of pro-IL-1 $\beta$ . The latter is cleaved to mature IL-1 $\beta$  by caspase 1 in the cytosol, which influences the production of a number of pro-inflammatory mediators, such as TNF- $\alpha$ , IL-6 and NOS. This characterizes the onset of the inflammatory reaction. GJs can transfer ATP between neighboring cells. HCs can release ATP into the extracellular environment after opening by pathogenic stimuli. ATP can then interact with P2X7 purinergic receptors at the cell plasma membrane and can influence the inflammatory process. (ATP, adenosine triphosphate; DAMPs, damage-associated molecular patterns; IL, interleukin; NF, nuclear factor; NOS, nitric oxide synthase; PAMPS, pathogen-associated molecular patterns; TNF, tumor necrosis factor).

# Table 1Connexin expression in different organs.

### (Cx, connexin).

Organ	Cell type	Cx species	Reference
Brain	Astrocytes	Cx30, Cx43	(Dermietzel et al., 1991, Nagy and Rash, 2000)
	Microglial cells	Cx26, Cx32	(Eugenín et al., 2001, Parenti et al., 2002, Garg et al., 2005, Takeuchi et al., 2006, Kielian, 2008)
	Oligodendrocytes	Cx32, Cx47, Cx29	(Dermietzel <i>et al.</i> , 1989, Altevogt <i>et al.</i> , 2002, Odermatt <i>et al.</i> , 2003)
	Neurons	Cx36, Cx45	(Takeuchi and Suzumura, 2014)
	Blood-brain barrier endothelial cells	Cx37, Cx40, Cx43	(Little et al., 1995, Traub et al., 1998, Nagasawa et al., 2006, De Bock et al., 2014)
	Blood-brain barrier pericytes	Cx37, Cx40, Cx43	(Little <i>et al.</i> , 1995, Traub <i>et al.</i> , 1998, Nagasawa <i>et al.</i> , 2006, De Bock <i>et al.</i> , 2014)
Heart	Smooth muscle cells	Cx40, Cx43, Cx45	(Gros and Jongsma, 1996, Severs et al., 2004)
	Cardiomyocytes	Cx40, Cx43, Cx45	(Gros and Jongsma, 1996, Severs et al., 2004)
Blood vessels	Endothelial cells	Cx43, Cx37, Cx40	(Chadjichristos et al., 2010, Scheckenbach et al., 2011)
	Smooth muscle cells	Cx43, Cx45, Cx40, Cx37	(Chadjichristos et al., 2010, Scheckenbach et al., 2011)
Liver	Sinusoidal endothelial cells	Cx26, Cx43	(Hernández-Guerra et al., 2014)
	Hepatic arteries and portal vein endothelial cells	Cx37, Cx40	(Fischer et al., 2005, Shiojiri et al., 2006)
	Hepatocytes	Cx26, Cx32	(Kyoi et al., 1992, Ohkusa et al., 1995, Iwata et al., 1998, Radebold et al., 2001)
	Kupffer cells	Cx26, Cx43	(González et al., 2002, Eugenín et al., 2007)
	Stellate cells	Cx26, Cx43	(Fischer et al., 2005, Maes et al., 2015b)
Stomach and intestines	Stomach	Cx26, Cx32, Cx40, Cx43, Cx45	(Wang and Daniel, 2001, Cousins <i>et al.</i> , 2003, Liu <i>et al.</i> , 2010, Wang <i>et al.</i> , 2014)
	Foveolar cell	Cx32	(Fink et al., 2006)
	Small intestine	Cx26, Cx31, Cx57	(Filippov et al., 2003)
	Musculus externa cell	Cx40, Cx43	(Wang and Daniel, 2001, Liu et al., 2008)
	Myenteric plexus cell	Cx36, Cx40, Cx43, Cx45	(Wang and Daniel, 2001, Liu <i>et al.</i> , 2008, Frinchi <i>et al.</i> , 2013)
	Epithelial cell	Cx32, Cx37, Cx43	(Traoré et al., 2003, Husøy et al., 2004, Hakim et al., 2008)
	Interstitial cell of cajal	Cx43	(Seki and Komuro, 2002)
	Colon	Cx31, Cx31.9, Cx43	(Ismail et al., 2014, Li et al., 2015b)
	Musculus externa cell	Cx26, Cx40, Cx43	(Wang and Daniel, 2001, Mattii et al., 2013)
	Myenteric plexus cell	Cx36, Cx40, Cx43, Cx45	(Wang and Daniel, 2001, Frinchi <i>et al.</i> , 2013, McClain <i>et al.</i> , 2014)
	Epithelial cell	Cx26, Cx32, Cx37, Cx43	(Kanczuga-Koda <i>et al.</i> , 2004, Kanady <i>et al.</i> , 2015)
	Muscularis mucosa cell	Cx43	(Ismail et al., 2014)
	Interstitial cell of Cajal	Cx43	(Nemeth et al., 2000)

Cell type

Organ

	Reference
2x30, 2x40,	(Di <i>et al.</i> , 2001, Brandner <i>et al.</i> , 2004, Wang <i>et al.</i> , 2007, Churko and Laird, 2013, Martin <i>et al.</i> , 2014)
40	(Wright et al., 2009, Meyer et al., 2014, Cogliati

8		•	
Skin	Keratinocytes	Cx26, Cx30.3, Cx30, Cx31.1, Cx31, Cx40, Cx43, Cx45	(Di <i>et al.</i> , 2001, Brandner <i>et al.</i> , 2004, Wang <i>et al.</i> , 2007, Churko and Laird, 2013, Martin <i>et al.</i> , 2014)
	Fibroblasts	Cx43, Cx45, Cx40	(Wright <i>et al.</i> , 2009, Meyer <i>et al.</i> , 2014, Cogliati <i>et al.</i> , 2015, Tarzemany <i>et al.</i> , 2015)
	Melanocytes	Cx43	(Haass et al., 2004, Rezze et al., 2011, Penuela et al., 2012)
Kidney	Smooth muscle cells	Cx37, Cx45	(Arensbak et al., 2001, Hanner et al., 2010, Li et al., 2015a)
	Podocytes	Cx43, Cx45	(Hanner et al., 2010, Morioka et al., 2013, Yang et al., 2014)
	Pericytes	Cx37	(Zhang et al., 2006, Hanner et al., 2010)
	Mesangial cells	Cx40, Cx45	(Arensbak et al., 2001, Kurtz et al., 2007, Hanner et al., 2010, Morioka et al., 2013)
Lung	Alveolar epithelium	Cx26, Cx32, Cx43, Cx46	(Koval, 2002)
Eye	Lens epithelial cells	Cx43, Cx50	(Berthoud et al., 2014)
Immune cells	T-cells	Cx40, Cx43	(Oviedo-Orta et al., 2000)
	B-cells	Cx40, Cx43	(Oviedo-Orta et al., 2000)
	Monocytes	Cx43	(Navab et al., 1991)
	Macrophages	Cx37, Cx43	(Beyer and Steinberg, 1991, Alves <i>et al.</i> , 1996, Kwak <i>et al.</i> , 2002)
Pancreas	β-cells	Cx36, Cx43, Cx45	(Charollais et al., 1999)
	Exocrine pancreas	Cx32	(Frossard et al., 2003)
Skeletal muscle	Myoblasts	Cx39, Cx40, Cx43, Cx45	(Merrifield and Laird, 2015)
Bone	Osteocytes	Cx37, Cx43	(Krüger <i>et al.</i> , 2000, Paic <i>et al.</i> , 2009, Pacheco- Costa <i>et al.</i> , 2014)
	Osteoblasts	Cx37, Cx43, Cx45, Cx46	(Civitelli <i>et al.</i> , 1993, Donahue <i>et al.</i> , 1995, Krüger <i>et al.</i> , 2000, Chaible <i>et al.</i> , 2011, Plotkin and Bellido, 2013)
	Osteoclasts	Cx37, Cx43	(Paic et al., 2009, Pacheco-Costa et al., 2014)
	Chondrocytes	Cx32, Cx43, Cx45, Cx46	(Mayan et al., 2013)

Cx species

# Table 2Effects of inflammation on connexins and their channels.

(Cx, connexin; FGF, fibroblast growth factor; GJIC, gap junctional intercellular communication; HC, hemichannel; IFN, interferon; IL, interleukin; LPS, lipopolysaccharide; mRNA, messenger ribonucleic acid; TGF, transforming growth factor; TNF, tumor necrosis factor).

Tissue	Model	Outcome	Reference
	Multiple sclerosis autoimmune encephalitis in mice	<ul> <li>↓ Cx32-based and Cx47-based</li> <li>GJs in oligodendrocytes</li> <li>↓ Cx43-based GJs in astrocytes</li> </ul>	(Markoullis <i>et al.</i> , 2012a)
	Multiple sclerosis patients	<ul> <li>↓ Cx32-based and Cx47-based</li> <li>GJs in oligodendrocytes</li> <li>↑ Cx30 and Cx43 protein in cortical lesions</li> </ul>	(Lieury <i>et al.</i> , 2014, Markoullis <i>et al.</i> , 2014)
	Rasmussen encephalitis patients	↓ Cx32 protein in cortex = Cx26 protein in cortex	(Cepeda et al., 2015)
	Intracerebroventricular injection of LPS in rats	<ul> <li>↑ Cx32 mRNA in hippocampus</li> <li>↑ Cx30 and Cx32 mRNA in hippocampus</li> <li>↓ Cx43 protein in hippocampus</li> </ul>	(Abbasian <i>et al.</i> , 2013) (Abbasian <i>et al.</i> , 2012) (Sayyah <i>et al.</i> , 2012)
	IL-1β-treated primary human fetal astrocytes	↓ GJIC ↓ Cx43 mRNA and protein	(John <i>et al.</i> , 1999, Duffy <i>et al.</i> , 2000)
	TNF-a-treated primary rat astrocytes	↓ GJIC Cx43 phosphorylation	(Haghikia <i>et al.</i> , 2008b)
	IL-1 $\beta$ and TNF- $\alpha$ -treated primary mouse astrocytes	↓ Cx43 protein and GJIC	(Même et al., 2006)
	LPS-treated primary rat astrocytes	↓ GJIC	(Bolaños and Medina, 1996)
	TNF- $\alpha$ and IFN- $\gamma$ -treated spinal rat astrocytes	$\downarrow$ Cx43 mRNA, protein and GJIC	(Zhang <i>et al.</i> , 2013b, Zhang <i>et al.</i> , 2015)
Brain	LPS-treated co-culture of rat primary astrocytes and rat primary microglia	↓ БЛС	(Haghikia <i>et al.</i> , 2008a, Hinkerohe <i>et al.</i> , 2010)
	LPS-treated co-culture of mouse primary astrocytes and mouse primary microglia	↓ GJIC ↑ HC activity	(De Vuyst <i>et al.</i> , 2007, Fruscione <i>et al.</i> , 2011) (Retamal <i>et al.</i> , 2007, Froger <i>et al.</i> , 2009)
	LPS-treated primary neonatal astrocytes	↓ Cx43 mRNA, protein and GJIC	(Liao et al., 2010)
	LPS-treated mouse microglia	↓ Cx32 mRNA, protein and GJIC	(Takeuchi et al., 2006)
	S. aureus-treated mouse brain slices	<ul> <li>↑ HC activity</li> <li>↓ GJIC</li> <li>↑ Cx43 and Cx30 protein</li> </ul>	(Karpuk <i>et al.</i> , 2011)
	Peptidoglycan-treated mouse primary microglia	<ul> <li>↓ GJIC</li> <li>↓ Cx43 and Cx30 mRNA and protein</li> <li>↑ Cx26 mRNA and protein</li> </ul>	(Garg et al., 2005)
	Protozoan-treated rat astrocytes and leptomeningeal cells	↓ GJIC	(Campos de Carvalho et al., 1998, Mele and Madrenas, 2010)
	Human immunodeficiency virus-infected human astrocytes	↑ Cx43-based HC activity ↓ GJIC	(Orellana et al., 2014)
	Mouse hepatitis virus-infected astrocytes and mice	↓ Cx43 protein ↓ GJIC	(Basu et al., 2015)
	Peptidoglycan-treated immortalized mouse endothelial cells	↑ Cx43-based HC activity	(Robertson et al., 2010)

Tissue	Model	Outcome	Reference
	Spinal cord injury in rats	↑ Cx43 protein and mRNA in astrocytes = Cx32 and Cx36 protein and mRNA	(Lee et al., 2005)
	FGF-1-treated spinal astrocytes	↑ Cx43-based HC activity	(Garré et al., 2010)
	Injection of LPS in rats	↓ Cx43 mRNA	(Fernandez-Cobo <i>et al.</i> 1999)
	TNF-a-treated rat myoblast cell line	↓ Cx43 promotor activity	(Fernandez-Cobo <i>et al.</i> 1999)
Heart	$TGF$ - $\beta$ -treated mouse embryotic cardiomyocytes	↓ GJIC	(Waghabi et al., 2009)
	T. cruzi-infected mouse embryotic cardiomyocytes	↓ GJIC	(Waghabi et al., 2009)
	T. cruzi-infected patients	↓ Cx43 protein	(Waghabi et al., 2009)
	T. cruzi-infected mouse cardiomyocytes	<ul> <li>↑ Cx43 protein on short term</li> <li>↓ Cx43 protein on long term</li> </ul>	(Adesse et al., 2008)
	Hyperlipidemic mice	<ul> <li>↓ Cx40 protein in endothelium</li> <li>↓ Cx37 protein in endothelium</li> <li>↑ Cx43 protein in endothelium</li> </ul>	(Yeh et al., 2003)
	Atherosclerotic mice	<ul> <li>↓ Cx40 protein in endothelium</li> <li>↓ Cx37 protein in endothelium</li> </ul>	(Kwak et al., 2002)
	Endothelium exposed to oxidative stress, prothrombotic molecules and cytokines	<ul> <li>↓ Cx40 protein</li> <li>↓ Cx37 protein</li> </ul>	(Hou et al., 2008)
Blood vessels	Coronary atherosclerosis patients	↑ Cx43 protein in coronary artery	(Blackburn et al., 1995
	LPS-injected rats	↑ Cx40 protein in aorta	(Frimmel et al., 2014)
	TNF-a-treated human umbilical vein endothelial cells	↓ Cx37 mRNA ↓ Cx40 mRNA	(van Rijen <i>et al.</i> , 1998)
	LPS-injected mice	<ul> <li>↓ Cx37 protein in aortic endothelium</li> <li>↓ Cx40 protein in aortic endothelium</li> </ul>	(Simon et al., 2004)
	LPS-treated mice	<ul> <li>↓ Cx32 and Cx26 protein</li> <li>↓ Cx32 mRNA</li> <li>↓ GJIC</li> </ul>	(De Maio <i>et al.</i> , 2000, Correa <i>et al.</i> , 2004)
	Hepatitis patients	↓ Cx32 protein	(Yamaoka <i>et al.</i> , 2000a Nakashima <i>et al.</i> , 2004
	IL-1β-treated primary hepatocytes	↓ Cx32 protein	(Yamamoto <i>et al.</i> , 2004)
	IL-1, IL-6 and TNF-a-treated immortalized hepatocytes	↑ Cx26 mRNA	(Temme <i>et al.</i> , 1998)
Liver	LPS-treated mice	↑ Cx26 mRNA	(Temme et al., 2000)
11401	LPS and IL-1 $\beta$ -treated primary stellate cell cultures	↑ Cx43 mRNA	(Fischer et al., 2005)
	LPS-treated primary Kupffer cell cultures	↑ Cx43 mRNA	(González <i>et al.</i> , 2002, Eugenín <i>et al.</i> , 2007)
	LPS and IFN- $\gamma$ -treated primary Kupffer cell cultures	↑ Cx43 protein and mRNA	(Eugenín <i>et al.</i> , 2007)
	Acetaminophen-treated mice	<ul> <li>↑ Cx43 protein and mRNA in liver</li> <li>↑ Cx43 protein in hepatocytes</li> <li>↓ Cx32 and Cx26 protein and mRNA in liver</li> </ul>	(Maes <i>et al.</i> , 2016a)
Stomach and intestines	Atrophic gastritis in rats	↓ Cx32 protein	(Nagahara <i>et al.</i> , 1996 Miwa <i>et al.</i> , 1997)

Tissue	Model	Outcome	Reference
	Intestinal inflammation in mouse	↓ Cx43 protein in colonic epithelium	(Sedhom <i>et al.</i> , 2013)
	Necrotizing enterocolitits in mouse	<ul> <li>↓ Cx43 protein in enterocytes</li> <li>↓ GJIC</li> </ul>	(Leaphart et al., 2007)
	<i>S. flexneri</i> -infected human Cx26-transfected HeLa cells	↑ HC activity	(Tran Van Nhieu <i>et al.</i> , 2003, Man <i>et al.</i> , 2007)
	<i>S. flexneri</i> -infected human mutated Cx26-transfected HeLa cells	= HC activity	(Man et al., 2007)
	<i>S. flexneri</i> -infected human Cx30-transfected HeLa cells	= HC activity	(Man et al., 2007)
	<i>S. flexneri</i> -infected human Cx31-transfected HeLa cells	= HC activity	(Man et al., 2007)
	<i>S. flexneri</i> -infected human Caco-2/TC7 intestinal epithelial cells	↑ HC activity	(Clair et al., 2008)
	Yersinia enterocolitica-infected Cx43-transfected human cells	<ul> <li>↑ HC activity</li> <li>↑ Cx43 phosphorylation</li> </ul>	(Wong and Isberg, 2005)
	Helicobacter pylory-infected human gastric epithelial cells	↓ GJIC	(Yokoyama <i>et al.</i> , 2005)
	Wound healing in rat	<ul> <li>↑ Cx26 protein in epidermis</li> <li>↑ Cx30 protein in epidermis</li> </ul>	(Coutinho <i>et al.</i> , 2003, Sutcliffe <i>et al.</i> , 2015)
	Wound healing in human	<ul> <li>↑ Cx26 protein in skin slices</li> <li>↑ Cx30 protein in skin slices</li> </ul>	(Brandner <i>et al.</i> , 2004, Sutcliffe <i>et al.</i> , 2015)
	Wounded epidermis of rat	↓ Cx43 protein	(Goliger and Paul, 1995)
	Wounded epidermis of mice	↓ Cx43 protein	(Coutinho et al., 2003)
	Wounded epidermis of human	↓ Cx43 protein	(Neub et al., 2007)
Skin	Diabetic wound in rat	<ul> <li>↓ Cx43 protein in epidermis</li> <li>↓ Cx26 protein in epidermis</li> <li>↑ Cx43 protein in dermis</li> </ul>	(Wang et al., 2007)
	Peptidoglycan ( <i>S. epidermidis</i> )-treated mouse endothelial cells	<ul> <li>↑ GJIC</li> <li>↑ HC activity</li> <li>↑ Cx43 protein</li> </ul>	(Robertson et al., 2010
	Peptidoglycan ( <i>S. epidermidis</i> and <i>S. aureus</i> )-treated keratinocytes	↑ Cx26-based HCs	(Donnelly et al., 2012)
	Peptidoglycan ( <i>S. epidermidis</i> and <i>S. aureus</i> )-treated HeLa cells	↑ Cx26-based HCs	(Donnelly et al., 2012)
	LPS-treated rat kidney epithelial cells	↓ Cx43	(Gerl et al., 2014)
	LPS-treated rat kidney epithelial cells	↑ Cx43	(Fernandez-Cobo <i>et al</i> 1998)
	Glucose-treated human cortical collecting duct cells	↑ Cx43 protein and mRNA through TGF-β1	(Hills et al., 2009)
Kidney	Chronic kidney-diseased mice	↓ Cx37 protein and mRNA	(Toubas et al., 2011)
	Chronic kidney-diseased patients	↑ Cx43 protein	(Abed et al., 2014b)
	TGF-β1 human collecting duct cells	↑ Cx43 protein ↑ GJIC	(Hills et al., 2009)
	Tubulointerstitial inflammation in humans	↑ Cx43 protein	(Hillis <i>et al.</i> , 1997a)
	Ovalbumin-induced allergic airway disease in mice	↓ Cx37 protein and mRNA	(Park et al., 2007)
Lung	LPS-treated human pulmonary endothelial cells	↑ Cx43 protein ↑ GJIC	(O'Donnell <i>et al.</i> , 2014 Kandasamy <i>et al.</i> , 2015)

Tissue	Model	Outcome	Reference
	Acute lung injury in rabbit	↓ Cx40 protein	(Rignault et al., 2007)
	TNF-a-exposed human corneal fibroblasts	↓ Cx43 protein	(Kimura et al., 2013)
	Glucose-treated retinal pigment epithelial cells	↓ Cx43 protein ↓ GJIC	(Losso et al., 2010)
Еуе	Intense light exposure in albino rats	<ul> <li>↑ Cx36 protein in inner plexiform layer</li> <li>↓ Cx45 protein in retina</li> <li>↑ Cx43 protein in choroid</li> </ul>	(Guo <i>et al.</i> , 2014)
	Diabetic retinal vessel	↓ Cx43 protein	(Tien <i>et al.</i> , 2014, Tien <i>et al.</i> , 2015)
Immune cells	LPS-treated monocytes	↑ Cx43 protein and mRNA	(Eugenín et al., 2003)
	LPS-treated human tonsillar B-lymphocytes	↑ Cx43 protein and mRNA	(Oviedo-Orta <i>et al.</i> , 2000)
Skeletal muscle	Denervated myofibers	<i>De novo</i> expression Cx39-based, Cx43-based and Cx45-based HCs	(Cea et al., 2013)
Bone	Osteoarthritic shoulders	↑ Cx43 protein in cartilage	(Casagrande <i>et al.</i> , 2015)
	LPS-treated fibroblast-like synoviocytes	↑ Cx43 mRNA	(Tsuchida et al., 2013)

# Table 3 Roles of connexins and their channels in inflammation.

(ATP, adenosine triphosphate; Cx, connexin; HC, hemichannel; IFN, interferon; IL, interleukin; LPS, lipopolysaccharide; TNF, tumor necrosis factor).

Tissue	Model	Outcome	Reference
	Cx43 blocking in cytokine-treated astrocytes	↓ neurotoxicity	(Froger et al., 2010)
Brain	Multiple sclerosis autoimmune encephalitits in Cx32 <sup>-/-</sup> mice	↓ loss of Cx47 and Cx43-based GJs	(Markoullis <i>et al.</i> , 2012a)
	Autoimmune encephalitic in astrocyte-specific Cx43 <sup>fl/fl</sup> Cx30 <sup>-/-</sup> mice	No alteration in susceptibility or severity of encephalitis	(Lutz et al., 2012)
	Cx43 HC-blocking peptides-treated ischemic near-term sheep	<ul> <li>↑ electroretinography outcome</li> <li>↓ seizure</li> <li>↓ status epilepticus</li> <li>↑ oligodendrocyte and neuronal survival</li> </ul>	(O'Carroll <i>et al.</i> , 2008, Davidson <i>et al.</i> , 2012)
	Astrocyte-specific Cx43 <sup>fl/fl</sup> mice	<ul> <li>↓ ATP-induced inflammation</li> <li>↓ macrophage and microglial</li> <li>recruitment</li> <li>↑ recovery following spinal cord</li> <li>injury</li> </ul>	(Huang et al., 2012)
	Connexin-blocking and Cx37/Cx43 knockdown in bradykinin-induced calcium oscillations in immortalized and primary brain endothelial cells	↓ calcium oscillations	(De Bock et al., 2011)
Heart	LipoxinA4-treated ischemic rats	<ul> <li>↓ IL-1β, IL-6, IL-8, TNF-α, and oxidative stress</li> <li>↑ Cx43 expression</li> <li>↑ Na<sup>+</sup>-K<sup>+</sup>-ATPase expression</li> </ul>	(Zhao <i>et al.</i> , 2013)
	Gap19-treated ischemia/reperfusion in mice	<ul> <li>↓ metabolic inhibition-enhanced</li> <li>HC opening</li> <li>↓ volume overload</li> <li>↓ cell death</li> </ul>	(Wang <i>et al.</i> , 2013c)
	Co-culture of murine macrophages and murine atrial myocytes subjected to mechanical stretch, carbenoxolone and apyrase	<ul> <li>↓ macrophage migration</li> <li>↓ increase extracellular ATP</li> </ul>	(Oishi et al., 2012)
	Atherosclerotic Cx37 <sup>-/-</sup> apolipoproteinE <sup>-/-</sup> mice	↑ aortic lesions	(Wong <i>et al.</i> , 2006, Pfenniger <i>et al.</i> , 2015)
	Cx37 <sup>-/-</sup> monocytes or macrophages introduced in hypercholesterolemic Cx37 <sup>+/+</sup> mice	↑ leukocytes in atherosclerotic plaque	(Chanson and Kwak, 2007)
Blood vessels	Polymorphism of Cx37 or blocking of Cx37-based HCs	↓ ATP release	(Chanson and Kwak, 2007)
	Endothelial-specific Cx40 <sup>-/-</sup> mice	Spontaneous atherosclerotic lesions in aorta	(Chadjichristos <i>et al.</i> , 2010)
	Atherosclerotic low density lipoprotein receptor $^{\prime\prime}Cx43^{+\prime-}$ mice	<ul> <li>↓ aortic atherosclerosis</li> <li>↓ atherosclerotic plaques</li> <li>↓ leukocytes</li> </ul>	(Kwak et al., 2003)
Liver	Non-alcoholic steatohepatitic Cx32 Tg rats	$\uparrow$ inflammation, oxidative stress	(Sagawa et al., 2015)
	Acetaminophen-treated Cx32 <sup>-/-</sup> mice	No effect on inflammation or oxidative stress	(Maes et al., 2016b)
	Acetaminophen-treated Cx43 <sup>+/-</sup> mice	Tendency of higher cell death, inflammation and oxidative stress	(Maes et al., 2016a)
Skin	Cx43 blocking in wound healing models	↓ wound healing time, inflammation	(Qiu <i>et al.</i> , 2003, Mori <i>et al.</i> , 2006, Cogliati <i>et</i> <i>al.</i> , 2015)

Tissue	Model	Outcome	Reference
	Gap27-treated skin	↑ cell proliferation	(Evans and Leybaert, 2007, Wright <i>et al.</i> , 2009, Pollok <i>et al.</i> , 2011)
	ACT1-treated chronic venous leg ulcers	<ul> <li>↑ fibroblast migration and proliferation</li> <li>↑ wound reepithelialization</li> </ul>	(Ghatnekar <i>et al.</i> , 2015)
	aCT1-treated skin	<ul> <li>↓ inflammatory response,</li> <li>↓ area of scar progenitor tissue restoration of dermal structure</li> </ul>	(Ongstad et al., 2013)
	Cx43 <sup>+/-</sup> mice	↑ wound healing	(Cogliati et al., 2015)
	Chronic kidney diseased Cx43 <sup>+/-</sup> mice	<ul> <li>↓ monocyte infiltration</li> <li>↓ fibrosis</li> </ul>	(Abed et al., 2014b)
Kidney	Cx43 antisense-treated chronic kidney diseased mice	↑ renal function	(Abed et al., 2014b)
	Cx43-specific blocking in chronic kidney diseased mice	<ul> <li>↓ monocyte adhesion</li> <li>↓ profibrotic pathways</li> </ul>	(Abed et al., 2014b)
	Endothelial-specific Cx43 <sup>-/-</sup> mice	↓ calcium wave propagation	(Parthasarathi <i>et al.</i> , 2006)
Lung	LPS-induced lung inflammation in endothelial-specific $Cx43^{-/-}$ mice	↓ neutrophil recruitment	(Sarieddine et al., 2009
	LPS-treated endothelial-specific Cx40 <sup>-/-</sup> in mice	↑ migration of neutrophils from blood to lungs	(Chadjichristos <i>et al.</i> , 2010)
	Cx43 blocking in glaucoma trabeculectomy surgery in rabbit	↓ scarring ↓ Cx43 upregulation	(Deva et al., 2012)
	aa-carboxy terminus 1-treated-rats of corneal inflammation	<ul> <li>↓ healing time</li> <li>↓ inflammation</li> </ul>	(Moore <i>et al.</i> , 2013)
	Cx43 antisense oligonucleotides-treated cornel scrape wounds	<ul> <li>↑ epithelial recovery</li> <li>↓ oedema</li> <li>↓ myofibroblast differentiation and proliferation</li> </ul>	(Grupcheva et al., 2012
Eye	a-carboxy terminus 1-treated corneal-wounded rats	<ul> <li>↓ healing time</li> <li>↓ inflammation</li> </ul>	(Moore <i>et al.</i> , 2013)
	Cx43 antisense oligonucleotides-treated rabit model of glaucoma	<ul> <li>↓ myofibroblast production</li> <li>↓ scarring</li> </ul>	(Deva et al., 2012)
	Cx43 antisense oligonucleotides-treated trabeculectomy patients	↓ scarring Long term maintenance of normal intraocular pressure	(Becker <i>et al.</i> , 2016)
	Peptide5-treated rat model of retina ischemia/reperfusion	<ul> <li>↓ vessel leak</li> <li>↓ inflammation</li> <li>↑ neuronal survival</li> </ul>	(Chen <i>et al.</i> , 2013, Chen <i>et al.</i> , 2015)
	18β-glycyrrhetinic acid or Cx mimetic peptides-treated human lymphocytes	$\downarrow$ immunoglobulins M, G and A	(Oviedo-Orta <i>et al.</i> , 2001)
Immunecells	Gap27-treated dendritic cells exposed to IFN- $\gamma$ and LPS	<ul> <li>↓ activation</li> <li>↓ antigen presentation</li> </ul>	(Matsue et al., 2006)
	Activated polymorphonuclear leukocytes from Cx43 <sup>fl/fl</sup>	$\downarrow$ extracellular ATP release	(Eltzschig et al., 2006)
Pancreas	Cx32 <sup>-/-</sup> mice	Acute pancreatitis	(Frossard et al., 2003)
Skeletal muscle	Cx43 <sup>fl/fl</sup> Cx45 <sup>fl/fl</sup> mice	$\downarrow$ denervation	(Cea <i>et al.</i> , 2013)
Bone	Cx43 small interfering RNA-treated arthritic rats	↓ arthritis	(Tsuchida et al., 2013)
DOLC	Cx43 small interfering RNA-treated synovial fibroblasts	$\downarrow$ expression inflammatory genes	(Gupta et al., 2014)